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Worldwide incidence of breast cancer is higher than incidence of other malignancies among 
women. In the Netherlands approximately one out of eight women will develop breast 
cancer during life [1]. Five to ten per cent of all breast cancers are hereditary. In the 
Netherlands, approximately 20% of familial breast cancer is caused by BRCA1, 5% is 
caused by BRCA2 and the remainder of 75% is non-BRCA1/BRCA2 [2]. Although the 
incidence has increased, mortality has decreased during the last two decades and at the 
moment the risk of dying of breast cancer is 1 of 26 [3]. This reduction in mortality is partly 
due to early detection of malignancies in screening and partly due to more and better 
adjuvant therapies [4]. 
 
Mammography 
Mammography is the primary imaging modality for the early detection of breast cancer. 
Despite advances in mammographic techniques (digital), mammography still has its 
limitations with regard to both sensitivity (39%-86%) and specificity (88%-94%), which 
depends on age and breast density [5,6,7]. Younger women have more fibroglandular 
tissue, resulting in a dense mammogram, with a low sensitivity.  
A diagnostic mammographic examination usually consists of craniocaudal and mediolateral 
oblique views in accordance with the National Breast Cancer Consultation in the 
Netherlands (NABON) and the American College of Radiology (ACR) standards [8,9]. 
Today, the ACR Breast Imaging Reporting and Data System (BI-RADS) is the 
communication tool in mammography reports. Each mammographic feature is described in 
the BI-RADS lexicon. The lexicon includes the following mammographic images: masses, 
micro/macrocalcifications, architectural distortions and special cases including ductal 
ectasia, intramammary lymph node or focal asymmetric density. After mammographic 
assessment by the radiologist, the mammograms are coded using the ordered categories of 
the ACR BI-RADS lexicon: category 1, negative (normal finding); category 2, benign 
finding; category 3, probably benign; category 4, suspicious finding; category 5, highly 





The diagnostic work-up of breast lesions depends on the BI-RADS classification of the 
breast lesions. The guideline for non-invasive diagnostic tests for breast abnormalities of 
the Agency for Health Care Research and Quality in the United States (AHRQ) and the 
guideline of the NABON state that breast lesions classified as BI-RADS 1 and 2 require no 
further work-up or follow-up other than routinely required [8,10]. The probability of a BI-
RADS 3 lesion being cancer is considered to be less than 2 %. The work-up of a BI-RADS 
3 lesion should be a biopsy or follow up mammography after six months [8,10]. In practice, 
the work-up of BI-RADS 3 lesions is decided by the possibilities for biopsy procedures, but 
also the wish of the patient and the preference of the radiologist. The additional value of 
breast Magnetic Resonance Imaging (MRI) as a non-invasive tool for the work-up of BI-
RADS 3 lesions is still under debate [8,10]. The chance of malignancy for a BI-RADS 4 
lesion varies from 2 to 95% and for a BI-RADS 5 lesion the chance of malignancy is higher 
than 95%. Therefore, the work-up for these categories requires an invasive (biopsy) 
procedure [8,10]. This biopsy procedure cannot be replaced by breast MRI, because 
histology is obligatory in these cases.  
BI-RADS classification remains a radiological classification with disregard of clinical and 
prognostic factor. Inter and intra observer variability thus is a recognised problem in images 
which are difficult to classify, especially in the BI-RADS 3 and 4 categories [11-15]. In 
conjunction with this limited accuracy of both physical examination and mammography 
results in a large majority of patients referred for biopsy with a BI-RADS 3 lesion to a final 
(pathologically proven) benign diagnosis.  
 
Breast Magnetic Resonance Imaging 
Breast MRI has emerged as a clinically useful additional diagnostic modality [16]. At 
present the major validated clinical indications for breast MRI are: the identification of 
breast cancer in high risk patients, the evaluation of multicentricity or multifocality in 
primary breast cancer detected by other methods, the detection and location of 
mammographic and ultrasound occult cancer in women with axillary metastases, the 
evaluation of treatment response during neoadjuvant chemotherapy, the evaluation of 
nipple discharge, imaging of the breast after conservative therapy, imaging of prothesis and 





evidence supports the use of breast MRI for specific clinical indications, although data are 
lacking to support the use of MRI for clinical scenarios [17,18]. It is not yet common 
practice to use breast MRI as problem solving modality, because thorough data validating 
its use in the case of challenging or inconclusive mammographic findings are not yet 
available [21-27]. 
Kuhl [16] described in detail why the evidence for the effectiveness of breast MRI in 
helping to solve focal mammographic problems is relatively weak. The reason is that 
ultrasonography- or mammography-guided core or vacuumbiopsy can obtain histological 
proof of equivocal lesions. A variety of minimally invasive procedures is widely available, 
relatively safe, inexpensive and giving diagnosis without surgical intervention. 
Furthermore, breast MRI has its limitations which include higher costs, longer examination 
time, and lower availability when compared with mammography and ultrasound [16,17]. 
However, in general MRI can be used as problem solving modality when the findings of 
conventional imaging are inconclusive, because the sensitivity of breast MRI, which 
usually exceeds 90%, is the highest of all imaging techniques for breast lesions [21,28,29]. 
Furthermore, a negative breast MRI meets a sufficiently high negative predictive value 
(NPV) (91.7%-100%) for non-calcified breast lesions to safely rule out malignancy 
[24,27,30,31] and thus prevent unnecessary invasive diagnostic procedures.  
As for mammography and ultrasound, also for contrast-enhanced MRI an ACR BI-RADS 
breast lexicon was published in 2003 based on the same objectives and methodology [9]. 
The lexicon includes the following MR findings: focus/foci, mass enhancement and non-
mass-like enhancement. For imaging analysis the dynamic breast MR images are used. In 
the contrast-enhanced dynamic sequence the uptake of contrast medium in breast lesions is 
followed in time. With the use of the dynamic breast MR images the morphological 
characteristics (shape, margin, spatial distribution and internal architecture) and the 
enhancement pattern of breast lesions are assessed [32-34]. Specific patterns of dynamic 
enhancement curves have been defined as persistent (type 1), plateau (type 2) and washout 
(type 3). Persistent enhancement is characterized by a monotonic increase, plateau 
enhancement by a constant level or “plateau” and the washout pattern has a characteristic 
peak followed by an immediate decrease in the signal intensity. Type 1 contrast 





enhancement is highly associated with breast cancers. However, a type 2 plateau 
enhancement pattern can be seen in both benign and malignant lesions [35-36]. After breast 
MRI evaluation by the radiologist, the MRI scans are also coded using the ordered 
categories of the ACR BI-RADS lexicon [9] and in analogy with the guideline of AHRQ 
and NABON the diagnostic work-up of breast lesions also depends on the BI-RADS 
classification [8,10].  
Because the postprocessing and interpretation of breast MRI data is time consuming and 
operator dependent, Computer Aided Detection (CAD) programs for MR imaging of breast 
lesions have been developed attempting to standardize and facilitate the interpretation of 
breast MRI [37,38]. 
 
Computer Aided Detection system 
The first CAD system for breast MRI (CADstream by Confimra, Inc) was launched in 
January 2003. It was not primarily developed to identify breast lesions, because most 
lesions are already detected by the radiologist. CAD for breast MRI can be defined as: “The 
automated analysis of enhancement kinetics, highlighting features related to malignancy” 
[38] and can, therefore, assist the radiologist in determining which lesions are benign and 
which are malignant. 
CAD systems help the radiologist to interpret breast MRI by automating extraction and 
interpretation of kinetic curves (the enhancement pattern of lesions). Using a CAD system, 
curve extraction and thresholding result in angiogenesis maps, which standardize the 
interpretation of breast MRI according to the BI-RADS lexicon. The angiogenesis maps 
provide a fast and reproducible way to take images from nearly any breast MR acquisition 
protocol and highlight features correlated with malignancy.  
The automated kinetic assessment of CAD generates a colour-coding based on the signal 
intensity changes in voxels during the enhancement of the breast tissue. Colour-coding 
provides a quick way for radiologists to find areas of significant enhancement and to 
interpret the kinetic curve (persistent, plateau and washout curve) [37,38]. The angiogenesis 
maps and colour-coding may help radiologists to identify lesions based on morphological 
and kinetic features and to make a more “evidence based” decisions regarding management 





should automatically identify (almost) all non-calcified lesions suspected of malignancy at 




Despite good evidence that breast MRI has a high NPV for non-calcified breast lesions, 
there is overlap in enhancement between benign and malignant breast lesions in a 
subcategory of patients [31-36]. Carcinomas tend to enhance faster and washout earlier than 
benign lesions do, but there are numerous exceptions to this pattern, for example 
fibroadenomas incidentally demonstrate an enhancement pattern similar to that of invasive 
cancer [39]. Therefore, in some cases, enhancement patterns may be equivocal and 
additional diagnostic methods may be needed for clarifications. This is mostly the case for 
breast lesions which are classified as BI-RADS 3 on MRI (unequivocal enhancement curve, 
type 2). The probability of MRI BI-RADS 3 lesions being cancer is not yet clear. Although 
this percentage should be less than 2 %, in the literature the chance of malignancy for MRI 
BI-RADS 3 lesion varies from 0.6% to 10% [30,40-43]. 
In addition to morphological and kinetical analysis, metabolic information is expected to be 
promising for the final diagnosis of breast lesions. In vivo proton (1H) MR spectroscopy of 
the breast provides metabolic information about the investigated tissue in a non-invasive 
manner. It has shown that substantial levels of choline-containing compounds can be 
detected in breast cancer, whereas choline generally is at least one order of magnitude 
lower in concentration in normal fibroglandular tissue [44]. However, it has been suggested 
that choline levels may not be highly elevated in all breast cancers. This might be 
determined by the biologic aggressiveness; thus, the ability of MR spectroscopy to 
demonstrate abnormal choline levels in breast cancer has been variable [45]. 
MR spectroscopic studies of the human breast have been either single-voxel [44-64] or 
multivoxel [65-70] investigations. Single-voxel spectroscopy is based on one voxel (one 
single rectangular volume of interest) placement in the breast lesion. In this voxel elevated 
levels of choline compounds which yield a signal at a chemical shift of 3.2 ppm are 
detected in the case of malignant tumor [46,47]. With rare exceptions [44,47,55,57], in the 





documented in, at best, a semiquantitative fashion such as assessment of the signal-to-noise 
ratio in the choline peak, peak visibility, or nonreferenced arbitrary peak area units. In 
several single-voxel MR spectroscopic studies performed on 1.5T MR imagers, 
investigators have reported sensitivities of 70%-100% and specificities of 82%-100% [46-
52,56]. However, the single-voxel technique has limitations in terms of lesion coverage, 
which may affect the sensitivity of assessing choline from just one voxel in view of tumor 
heterogeneity [65]. Furthermore, the study of local pathology by single-voxel MR 
spectroscopy will always be hampered by the impossibility to study tissue heterogeneity or 
to compare the metabolite signals in a breast lesion directly to those in unaffected tissue 
[65]. Problems inherent to single-voxel MR spectroscopy may thus have influenced the 
diagnostic accuracy (sensitivity, specificity) of this novel MRI method in a negative way. 
Multivoxel technique or chemical-shift imaging (CSI) can be used to acquire spectroscopic 
information from a large volume of interest subdivided into an array of voxels measured in 
a single measurement, and hence is suitable for analyzing the regional distribution of tumor 
metabolites. Therefore, the multivoxel MR spectroscopic technique is suitable for analyzing 
the regional distribution of tumor metabolites and to study tissue heterogeneity. Another 
opportunity of multivoxel MR spectroscopy is presented by the possibility of metabolic 
mapping of breast lesions. Although it is commonly used in the brain and prostate, only six 
studies with breast lesions have been reported [65-70]. In 3 of these studies [65-67] the 
diagnostic value of combined contrast-enhanced MRI and multivoxel MR spectroscopy in 
evaluating breast lesions is assessed. It appears that multivoxel MR spectroscopy is a 
promising technique for classification of breast lesions when contrast-enhanced MRI results 
are equivocal. However, multivoxel MR spectroscopic studies, while potentially allowing 
for truly quantitative tissue characterization, have up to now also been far from quantitative 
with the use of the choline signal-to-noise ratio as measure of tumour activity [65-70]. 
Quantitative tissue characterization is necessary because choline signals are not only 
detected in malignant lesions but also in benign breast lesions and normal fibroglandular 
tissue. Therefore, the presence of a Cho-related peak in breast MR spectroscopy is not 
sufficient for a final non-invasive diagnosis of malignancy. 
With the development of a protocol for quantitative multivoxel MR spectroscopy for the 





be determined more accurately leading to enhancement of the diagnostic use of MR 
spectroscopy. A quantitative measurement of choline concentrations would thus increase 
the accuracy of contrast-enhanced MRI in the assessment of breast lesions. In this way it 
should be possible to exclude patients with benign breast lesions from further invasive 
diagnostic work-up. 
 
Purpose and outline 
 
The focus of this PhD thesis is to investigate new non-invasive diagnostic developments to 
prevent unnecessary invasive procedures in breast cancer diagnostic work-up for women 
with a probably benign (BI-RADS 3) breast lesion. Therefore, in a meta-analysis (chapter 
2) the usefulness of breast MRI as a problem solving modality in patients with 
mammographic BI-RADS 3 lesions is analyzed. In chapter 3 the NPV of breast MRI in 
mammographic BI-RADS 3 lesions is investigated. The purpose is to determine whether 
breast MRI can provide a sufficient NVP to safely rule out malignancy and decrease the 
percentages of invasive diagnostic procedures. In a systematic review and meta-analysis in 
chapter 4 the sensitivity and specificity of radiologist and resident in the assessment of 
breast lesions on MRI with and without a commercial available CAD system is evaluated. 
In chapter 5 a quantitative multivoxel MR spectroscopic method for the examination and 
metabolic mapping of breast lesions is presented. The optimal cutoff of choline 
concentration in quantitative multivoxel MR spectroscopic data to safely prove benignancy 
in breast lesions is examined in chapter 6. Lastly, in chapter 7 the added value of 
quantitative multivoxel MR spectroscopy in breast MRI is investigated. If multivoxel MR 
spectroscopy can increase the accuracy of breast MRI, this could prevent unnecessary 
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The probability of a mammographic Breast Imaging Reporting and Data System (BI-
RADS) 3 lesion being cancer is considered to be less than 2 %. Therefore, the work-up of a 
mammographic BI-RADS 3 lesion should be biopsy or follow-up mammography after 6 
months. However, most patients referred for biopsy have benign disease. Although the 
negative predictive value (NPV) of magnetic resonance imaging (MRI) is highest of all 
imaging techniques, it is not yet common practise to use breast MRI as problem-solving 
modality to exclude patients for further diagnostic work-up. Therefore, in this meta-
analysis, the usefulness of breast MRI as a problem-solving modality in mammographic BI-
RADS 3 lesions is investigated. After a systematic search only 5 out of 61 studies met the 
inclusion criteria. The NPV in 2 of those studies was reported to be 100%. It was concluded 
that MRI can be used as an adjunctive tool to mammographic BI-RADS 3 findings to 
exclude patients for further diagnostic work-up. The other 3 studies assessed the accuracy 
of MRI in mammographic BI-RADS 3 microcalcifications. These studies reported a NPV 
of MRI between 76% and 97%. Therefore, MRI cannot be implemented as a diagnostic tool 
to evaluate mammographic microcalcifications at this time. The first solid data indicate that 
breast MRI might be useful as a problem-solving modality to exclude patients with non-
calcified mammographic BI-RADS 3 lesions for further diagnostic work-up. However, 
further research is needed to verify these results. 






Mammography is the primary imaging modality for the early detection of breast cancer. 
Despite advances in mammographic techniques (digital), mammography still has its 
limitations with regard to both sensitivity (65.6-85.5%) and specificity (87.7-94.3%) [1,2]. 
Mammograms are coded using the ordered categories of the American College of 
Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) lexicon: 
category 1, negative; 2, benign finding; 3, probably benign; 4, suspicious finding; 5, highly 
suggestive of malignancy [3]. The diagnostic work-up of breast lesions depends on the BI-
RADS classification of the breast lesions. The guideline for non-invasive diagnostic tests 
for breast abnormalities of the Agency for Health Care Research and Quality in the United 
States (AHRQ) states that breast lesions classified as BI-RADS 1 and 2 require no further 
work-up or follow-up other than routinely called for [4]. The chance of a BI-RADS 4 lesion 
to be malignant varies from 2% to 95%, whereas this chance is over 95% for a BI-RADS 5 
lesion [4]. Therefore, the work-up for these categories demand a biopsy procedure. This 
biopsy procedure cannot be replaced by breast magnetic resonance imaging (MRI), because 
histology is obligatory in these cases [4]. The most difficult mammographic lesions are the 
lesions which are classified as BI-RADS 3. The probability of a BI-RADS 3 lesion being 
cancer is considered to be less than 2 %. For the work-up of BI-RADS 3 lesion biopsy or 
follow-up mammography after six months is advised [4]. In practice, the decision on the 
work-up of BI-RADS 3 lesions depends on the possibilities for biopsy procedures, the 
wishes of the patient and the preference of the radiologist. Most patients who are referred 
for a biopsy have benign disease because of the low predictive value of both physical 
examination and mammography [5,6]. The value of breast MRI in BI-RADS 3 lesions is 
not yet clear [4]. Breast MRI is emerging as a clinically useful additional diagnostic tool 
[4,7] and has an excellent sensitivity and negative predictive value (NPV), which usually 
exceeds 90% [8-10]. However, the overall specificity of breast MRI varies between 67% 
and 72% [8-10]. The diagnostic accuracy of breast MRI varies with the expertise of the 
radiologist and the particular patient population studied. It is important that breast MRI is 
used for those groups of patients for whom there is evidence of acceptable diagnostic 





increased risk for breast cancer [7,11-14]. As second-line modality, breast MRI can be used 
for the following indications: inconclusive findings in conventional imaging, preoperative 
staging, axillary node malignancy and unknown site of primary tumor, the evaluation of 
therapy response in the neoadjuvant chemotherapy setting [7,11-14], imaging of the breast 
after conservative therapy, prothesis imaging [7,13], nipple discharge [7,14] and MR-
guided biopsy and lesion localization [13]. Although the NPV of MRI in breast cancer is 
the highest of all imaging techniques [8;15,16] and in most of the cases a negative breast 
MRI excludes malignancy [17-19], it is not yet common practise to use breast MRI as 
problem-solving modality in excluding patients for further diagnostic work-up. 
Therefore, in this meta-analysis, the usefulness of breast MRI as a problem-solving 
modality in patients with mammographic BI-RADS 3 lesions is investigated. 
 
Materials and methods 
 
Search strategy 
A computerized search was performed to identify relevant studies in Medline and Embase 
up to 2010. The following strategy was followed in Medline: "Magnetic Resonance 
Imaging" [Mesh term] OR “Magnetic Resonance Imaging” [Text Word] OR “MRI” [Text 
Word] OR “MR imaging” [Text Word] AND "probably benign lesions" [Text Word] OR 
“microcalcifications” [Text Word] OR “inconclusive findings” [Text Word] AND 
“mammography” [Mesh term] OR “mammography” [Text Word] AND "Sensitivity and 
Specificity" [Mesh term] OR “specificity OR sensitivity” [Text Word]. In Embase the same 
strategy was used. All languages were considered.  
 
Eligibility criteria and study selection 
Medline and Embase were searched for studies that used breast MRI as problem-solving 
modality in mammographic BI-RADS 3 lesions. Studies were included if the following 
inclusion criteria were met: (1) all patients underwent a mammography and breast MRI; (2) 
study population had mammographic BI-RADS 3 lesions or mammographic BI-RADS 3 
microcalcifications; (3) accuracy, sensitivity, specificity, positive predictive value (PPV) 
and/or negative predictive value (NPV) was/were measured; (4) studies with original data 




which were published in peer-reviewed journals. The selected relevant studies were based 
on title, abstract and full paper. All selected studies were published in English language. 
The complete search yielded 61 studies, of which 9 studies were duplicates. Forty-one out 
of the 52 studies were excluded based on the title. From the 11 remaining studies the 
abstract or full paper was reviewed. Four studies were excluded because no BI-RADS 





In the 5 selected studies 376 breast lesions were reported, of which 213 were 
microcalcifications, 110 were asymmetric mammographic finding, 36 were non-calcified 
regular shaped lesions, 12 were architectural distortion and 5 were scar lesions. In 2 [22,23] 
studies mammographic BI-RADS 3 lesions were included; one [22] only included category 
3 lesions, the other [23] also included BI-RADS 0 and 4 lesions. In the other 3 [20,21,24] 
studies mammographic BI-RADS 3 microcalcifications were included but 
microcalcifications that were classified as BI-RADS 4 and 5 were also included (Table 1). 
 
Mammographic BI-RADS 3 lesions 
In one study [22], the role of MRI in the evaluation of mammographic BI-RADS 3 lesions 
was investigated. MRI was performed on 56 lesions described as BI-RADS 3 by 
mammography in 43 patients. The 56 mammographic BI-RADS 3 lesions were distributed 
into non-calcified regular shaped lesions (64.3%), focal asymmetric densities (21.4%), 
generalized microcalcifications (12.6%) and a cluster of tiny calcifications (1.7%). The 
sensitivity, specificity, accuracy, PPV and NPV of MRI in the determination of malignancy 
in these mammographic BI-RADS 3 lesions were calculated as 100%, 96.4%, 96.4%, 
33.3% and 100%, respectively. Gokalp et al. [22] concluded that MRI may be helpful in the 
evaluation of focal asymmetric densities as MRI confirmed that nine of the 12 
mammographic focal asymmetric densities were breast tissue and that the other 3 were 
masses. 
  
Table 1 Study characteristics (P, prospective; R, retrospective; c, consecutive; NR, not reported). 
 
 Study (first author, year of publication) 
 Moy 2009[23] Gokalp 2006[22] Akita 2009[20] Cilotti 2007[21] Uetmatsu 2007[24] 
No. of patients 115 43 53 55 96 
Study design R,c P,c NR NR P,c 
No. of lesions 115 56 50 55 100 
Mammographic findings  
Asymmetry 98 12 
Architectural distortion 12 
Scar lesion 5 
Non-calcified regular-shaped lesions 36 
Generalized calcifications  7 
A cluster of tiny calcifications  1 
Microcalcifications 50 55 100 
Mammogrraphic BI-RADS 
     0 78    
     1     
     2     
     3 15 56 9 23 55 
     4 22 41 25 27 
     5   7 18 
Gold standard Pathology Pathology, Pathology Pathology Pathology 
  FU 6 months 
Mammographya 
Sensitivity NR NR 100% 77% NR  
Specificity 80.7% NR 24% 59% NR 
PPV 8.7% NR NR 63% 67%  
NPV NR NR NR 74% 93% 
Accuracy 78.3% NR 44% 67.2% NR 
MRIa 
Sensitivity 100% 100% 85%b 73% NR 
Specificity 91.7% 96.4%  100%b 76% NR 
PPV 40% 33.3% NR 73% 86% 
NPV 100%  100% NR 76% 97% 
Accuracy 92.2% 96.4% 96%b 74.5% NR  
 
a
 In the analysis of Moy et al., Cilotti et al. and Uematsu et al. BI-RADS 3 lesions were considered as benign and BI-RADS 4 and 5 as malignant. 
b Mammography+MRI. 




Another study [23] evaluated the usefulness of breast MRI in cases of inconclusive 
mammographic or sonographic findings. In this study, not only mammographic BI-RADS 3 
lesions (n=15) were included, but also BI-RADS 4 lesions (n=22) and mammographic BI-
RADS 0 lesions (n=78). In total, 115 breast MRI scans were used as adjunctive tool and the 
findings were correlated with pathology. The equivocal mammographic findings for which 
MRI was performed were asymmetry without associated microcalcifications (85.2%), 
architectural distortion (10.4%) and change in the appearance of the site of a previous 
benign biopsy finding (4.3%). MRI had a sensitivity of 100%, NPV of 100% and compared 
with mammography had significantly higher specificity (91.7% versus 80.7%, p=0.029), 
PPV (40% vs 8.7%, p=0.032), and overall accuracy (92.2% vs 78.3%, p=0.00052). Moy et 
al. [23] concluded that breast MRI can be a useful adjunctive tool when equivocal findings 
at conventional mammography are asymmetry or architectural distortion. 
 
Mammographic BI-RADS 3 microcalcifications 
Three published studies [20,21,24] evaluated the role of MRI in patients with 
mammographic BI-RADS 3 microcalcifications. Akita et al. [20] included also 
mammographic BI-RADS 4 microcalcifications and Cilotti et al. [21] and Uetmatsu et al. 
[24] included mammographic BI-RADS 4 and 5 microcalcifications.  
In the study of Akita et al. [20] the clinical value of additional breast MRI in patients with 
microcalcifications on mammography and negative ultrasound findings was evaluated.  
Fifty patients with mammographic microcalcifications (9 BI-RADS category 3 and 41 BI-
RADS category 4) were included. These patients underwent MRI before stereotactic 
vacuum-assisted biopsy. Mammography had a sensitivity of 100%, a specificity of 24% and 
an accuracy of 44%, whereas mammography plus MRI had a sensitivity of 85%, a 
specificity of 100% and an accuracy of 96%. They concluded that breast MRI compared 
with mammography alone significantly improved the rate of diagnosis of malignancy in 
breast lesions which were detected as mammographic BI-RADS 3 or 4 microcalcifications 
[20].  
In the study of Uematsu et al. [24], breast MRI was performed in 100 microcalcifications 
detected at screening mammography in 96 patients. These patients also underwent a 





the basis of a BI-RADS category and the absence or presence of contrast uptake in the area 
of microcalcifications. NPV of BI-RADS mammography 3 was 93% versus 97% NPV of 
MRI (p=0.167). The PPV of contrast uptake of MRI was 86%, which is significantly higher 
than the 67% PPV of BI-RADS mammography 4 and 5 (p=0.033). Uematsu et al. [24] 
concluded that the imperfect PPVs and NPVs of MRI in the evaluation of 
microcalcifications detected at screening cannot replace stereotactic vacuum-assisted 
biopsy. 
Also Cilotti et al. [21] concluded that the PPV and NPV of MRI in the characterization of 
microcalcifications are not high. In their study, 55 patients with mammographic 
calcifications classified as BI-RADS categories 3, 4 or 5 underwent MRI and stereotactic 
vacuum-assisted biopsy. The sensitivity, specificity, PPV, NPV and diagnostic accuracy 
were 73%, 76%, 73%, 76% and 74.5%, respectively. Their conclusion is that MRI cannot 




The AHRQ guideline states that the work-up for mammographic BI-RADS 3 lesions should 
be biopsy or follow-up imaging after 6 months [4]. There is not yet a role for breast MRI, 
because ultrasonography- or mammography-guided core or vacuumbiopsy can obtain 
histological proof of a BI-RADS 3 lesion. A variety of minimally invasive procedures is 
widely available, relatively safe, inexpensive and provide a diagnosis without surgical 
intervention. Furthermore, breast MRI has its limitations, which include higher costs, 
longer examination time, and lower availability compared with mammography and 
ultrasound [7,11]. If breast MRI wants to be an effective addition to the work-up of a 
mammographic BI-RADS 3 lesion, the NPV of breast MRI must be sufficiently high to 
definitively rule out further work-up with biopsy. Although there were only 5 studies which 
investigated the usefulness of MRI as problem-solving modality in mammographic BI-
RADS 3 lesions, the NPV was 100% in non-calcified mammographic BI-RADS 3 lesions 
and 76-97% in mammographic BI-RADS 3 microcalcifications. On the other hand Kuhl [7] 
indicated that the evidence for the effectiveness of breast MRI is relatively weak in helping 
to solve mammographic problems, because in a multicenter trial of Bluemke et al. [8] the 




NPV was not high enough to exclude malignancy with sufficient confidence in case of an 
equivocal or suspicious lesion seen at conventional imaging. The diagnostic accuracy of 
MRI was studied in 821 patients with a suspicious mammographic BI-RADS 4 or 5 lesion 
(85%) or a suspicious clinical finding with a negative or benign conventional work-up 
(15%) before biopsy. MRI had a NPV of 85% with cancer missed in 48 of 329 negative 
MRI examinations. This NPV is not sufficiently high to avoid biopsy in suspicious 
mammographic BI-RADS 4 or 5 lesions [8]. This widely referenced multicenter study was 
performed in 14 hospitals from 1998 to 2001 and therefore used now outdated MR 
equipment. Furthermore, the study of Bluemke et al. [8] included patients with 
microcalcifications of the breast which have a negative influence on the NPV. In this meta-
analysis 3 studies [20,21,24] assessed the role of MRI in mammographic BI-RADS 3 
microcalcifications. These studies also included microcalcifications BI-RADS 4 and 5. A 
NPV between 76% and 97% was reported [21,24] in concordance with Bluemke results [8]. 
Therefore, MRI cannot be implemented as a problem-solving modality in mammographic 
microcalcifications at this time. Mammography and stereotactic biopsy remain the only 
techniques for characterising microcalcifications [21,24].  
According to Kuhl et al. [7] MRI can be useful as an additional tool in patients with 
calcifications: it can be helpful in demonstrating or excluding underlying invasive cancer, 
because MRI has a high NPV for invasive cancer. An important application of MRI 
associated with suspicious microcalcifications could be to evaluate disease extension [7].  
However, the studies which comply with the inclusion criteria of the meta-analysis, i.e. 
non-calcified mammographic BI-RADS 3 lesions [22,23], reported a NPV of 100% and 
concluded that MRI can be a useful tool in mammographic BI-RADS 3 lesions, especially 
when mammographic findings are asymmetry or architectural distortion [22,23].  
Although there are sparse data, the first solid data indicate that breast MRI might be useful 
as problem-solving modality to exclude patients with non-calcified mammographic BI-
RADS 3 lesions from further diagnostic work-up. However, further research is needed to 
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Purpose: The purpose of this study is to determine whether breast MRI can provide a 
sufficient NPV to safely rule out malignancy in mammographic BIRADS 3 lesions. 
Materials and methods: In a 3-years consecutive mammographic examination study 176 
out of 4391 patients had a lesion classified as BIRADS 3. 76 out of 176 patients underwent 
breast MRI as diagnostic work-up. Lesions which MRI classified as BIRADS 1 or 2 were 
considered negative for malignancy. Sensitivity, specificity, PPV and NPV were calculated. 
Results: In 27 out of 76 (35.5%) patients MRI showed no enhancement and was classified 
as BIRADS 1. In 25 (32.9%) patients MRI showed focal or mass enhancement classified as 
BIRADS 2. In these 52 (68.4%) patients no malignancy was found during at least 2 years 
study follow-up. The other 24 (31.6%) patients had a lesion classified as BIRADS≥3. 
Thirteen of these 24 lesions were malignant by pathology. MRI had a sensitivity of 100% 
(95% CI: 75-100%), specificity of 82.5% (95% CI: 71-91%), PPV of 54.2% (95% CI: 33-
74%) and NPV of 100% (95% CI: 93-100%). 
Conclusions: Breast MRI should be used in a diagnostic strategy for the work-up of 
noncalcified BIRADS 3 lesions. Malignancy is ruled out with a very high level of 
confidence in the majority of patients (68%), herewith avoiding invasive diagnostic 
procedures. 






Diagnostic mammography is commonly used to identify possible breast cancers in women 
and is the primary imaging modality for the early detection of breast cancer. However, 
mammography has its limitations with regard to both sensitivity (65.6-85.5%) and 
specificity (87.7-94.3%), which are depended on age and breast density [1,2]. 
Mammograms are coded using the ordered categories of the American College of 
Radiology (ACR)  Breast Imaging Reporting and Data System (BIRADS) lexicon: category 
1: negative; 2: benign finding; 3: probably benign; 4: suspicious finding; 5: highly 
suggestive of malignancy [3]. The diagnostic work-up of breast lesions depends on the 
BIRADS classification of the breast lesions. The guideline for non-invasive diagnostic tests 
for breast abnormalities of the Agency for Health Care Research and Quality in the United 
States (AHRQ) and the guideline of the National Breast Cancer Consultation in the 
Netherlands (NABON) state that breast lesions classified as BIRADS 1 and 2 require no 
further diagnostic work-up or follow-up other than routinely required. The work-up for a 
BIRADS 4 or BIRADS 5 lesion demands a biopsy procedure, because the chance of 
malignancy for a BIRADS 4 lesion varies from 2% to 95% and for a BIRADS 5 lesion 
higher than 95% [4,5]. The probability of a BIRADS 3 lesion to be malignant is considered 
to be less than 2%. Therefore, the work-up of a BIRADS 3 lesion can be a biopsy or 
follow-up mammography after six months. In practice, the work-up of BIRADS 3 lesions is 
decided on the possibilities for biopsy procedures, but also on the wish of the patient and 
the preference of the clinician. Because of the low predictive value of both physical 
examination and mammography, a large majority of patients referred for biopsy have a 
benign lesion [6,7]. 
Breast Magnetic Resonance Imaging (MRI) is emerging as a clinically useful additional 
diagnostic tool [5,8], but according to AHRQ the additional value of breast MRI in 
BIRADS 3 lesion is not yet clear [4,5]. There are sparse data available to support the use of 
breast MRI as problem solving modality in mammographic BIRADS 3 lesions [9,10] and 
therefore it has not been implemented in common practice. However, breast MRI has the 





In selected populations a negative breast MRI shows a sufficient high negative predictive 
value (NPV: 91.7-100%) to safely exclude malignancy [9,10,14,15].  
The purpose of this study is to determine whether breast MRI can be used as a problem 
solving modality for mammographic BIRADS 3 lesions by providing a sufficient negative 
predictive value (>98%) for early work-up and there by safely rule out malignancy and to 
decrease the percentages of invasive procedures.  
 
Materials and Methods 
 
Patient population 
Patients, referred with clinical suspicious for breast cancer, were included consecutively 
from January 2005 until January 2008 at the University Medical Center Groningen 
(UMCG). 4391 patients underwent a mammographic examination and diagnostic work-up 
at the department of radiology.  
Over this period in 188 patients mammograms were classified as BIRADS 3 (Table 1).  
 
 
Table 1 Mammographic BIRADS classification (2005-2008). 
 
BIRADS category                                                            Number of mammography examination                                 
 
0 need additional imaging evaluation                                       7 (0.2) 
1 negative                                                                                   89 (2.0) 
2 benign finding                                                                       3884 (88.4) 
3 probably benign                                                                      188 (4.3) 
4 suspicious abnormality                                                          112 (2.6) 





Note. Values in parentheses are percentage. 
 
 
Twelve women were excluded: 10 patients did not have a work-up in the UMCG and 2 
patients died of cardiovascular disease before study follow-up was done. Seventy-six out of 
176 patients with a mean age of 52 years (range, 30-73 years) underwent a breast MRI as 




diagnostic work-up of the BIRADS 3 lesion. The final diagnosis was confirmed by 
pathology or a clinical and diagnostic follow-up of at least 2 years. The remaining 100 
patients underwent different work-up strategies (biopsy procedure, surgical intervention, 
follow-up mammogram or ultrasound) (Fig.1). This study was approved by the Medical 
Ethical Committee of the University of Groningen. 
 
 
Fig. 1 Flow chart of patient inclusion and with reasons for exclusion. 
 4391 patients underwent mammography 
188 patients with mammographic BIRADS 3 lesion 
176 patients  
12 patients excluded: 
-  10 patients did not have a work-up in          
        UMCG 
-  2  patients died of cardiovasculair disease  
       before study follow-up was made 
76 patients with 76 lesions underwent MRI  
100 patients underwent different work-up: 
- biopsy procedure 
- follow-up mammogram or ultrasound 







Mammography was obtained on a mammomat Novation system with a Selenium detector 
(Siemens Medical Solutions, Erlangen, Germany). In all cases, at least standard 
mammography was performed in craniocaudal and mediolateral oblique views. The 
radiologist coded the mammograms by using the ordered categories of the ACR BIRADS 
lexicon (3). All imaging examinations were assessed by 3 breast radiologists, with at least 
10-20 years experience in breast imaging. 
 
MRI 
MR scans were obtained on a 1.5 Tesla whole body MR scanner (Avanto; Siemens Medical 
Solutions, Erlangen, Germany) using a dedicated bilateral breast coil with the patient in 
prone position. In cases of premenopausal women, the MRI was performed in the second 
week of the menstrual cycle. The standard MRI protocol included a T2 Turbo Spin Echo 
(TR/TE 4500/102ms, FOV 340mm and slice thickness 4mm) in the transversal plane. A T1 
weighted three-dimensional (3D) fast low-angle shot (FLASH) sequence (TR/TE/FA 
7.5ms/4ms/25deg, FOV 320mm and slice thickness 1.50mm, totally 1.08min) in the 
coronal plane was made before and 6 times after Gd intravenous contrast agent 
(0.2mmol/kg  Dotarem) administration. The contrast-enhanced dynamic sequence was 
performed approximately 30 seconds after injection and was followed by 5 additional 
consecutive sequences. The total duration of the dynamic study was approximately 8 
minutes. Subtracted images were obtained by subtracting pre-contrast images from the 
post-contrast images using the machines commercially available software. The protocol 
also included a T1-3D FLASH water excitation (TR/TE/FA 11ms/3.93ms/25deg, FOV 
350mm, slice thickness 0.90mm) in the transversal plane. MRI scans were coded using the 
ordered categories of the ACR BIRADS lexicon [3]. All imaging examinations were 
assessed by 2 breast radiologists, with at least 10 years experience in breast imaging. 
 
Image and data analysis 
Demography and indication for mammography were obtained from the patient records. In 
each case the category of findings for which the breast MRI was recommended was 




analyzed. The mammographic BIRADS 3 findings were noncalcified solid masses, 
asymmetric densities and microcalcifications [16]. 
The MR images were classified as normal if no enhancement was seen in the expected 
location of the mammographic finding (BIRADS 1) or only homogeneous or stippled 
enhancement was found in the breast, representing normal enhancing breast parenchyma or 
fibrocystic changes (BIRADS 2). The lesions which were detected on the MRI and 
corresponded with the area to the mammographic finding were classified as focus, mass 
enhancement or non-mass enhancement. From the enhancing lesion the location, lesion 
type, shape, border, distribution, internal enhancement and kinetic curves according to the 
BIRADS lexicon were assessed and the lesions were classified as BIRADS 3, 4 or 5 [3]. 
 
Statistical methods 
Lesions which MRI classified as BIRADS 1 or 2 were considered negative for malignancy. 
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) were calculated on the basis of final pathology reports or long-term clinical and 
diagnostic follow-up findings of at least 2 years. The 95% confidence intervals (CI) were 
calculated using the binomial distribution. Receiver operating characteristics (ROC) 
analysis was used to quantify the diagnostic accuracy of MRI for the assessment of 
mammographic BIRADS 3 lesions. Data were analyzed in STATA SE version 11.0 




Mammographic and MRI findings 
The 76 mammographic BIRADS 3 findings were assessed as a noncalcified solid mass 
(n=56, 73.7%), asymmetric density (n=12, 15.8%) or microcalcifications (n=8, 10.5%) 
(Table 2).  
In 37 (66.1%) out of 56 mammographic noncalcified solid masses MRI showed an 
enhancement. These 37 enhancements were foci in 22 (59.5%) patients, mass enhancement 
in 14 (37.8%) patients and non-mass enhancement in 1 (2.7%) patient. Nineteen (33.9%) 





In 9 (75%) out of 12 mammographic asymmetric densities were assessed by MRI as foci in 
4 (33.3%) patients and as mass enhancement in 5 (41.7%) patients. Three (25.0%) patients 
had no abnormal enhancement on MRI.  
In 5 (62.5%) out of 8 mammographic microcalcifications there was no abnormal 
enhancement seen on the MRI. Three (37.5%) patients with microcalcifications had a mass 
enhancement on the MRI (Table 3). 
 
 
Table 2 Mammographic BIRADS 3 findings. 
 
Mammographic BIRADS 3 findings  Number 
 
Noncalcified solid mass 56 (73.7) 
Asymmetric density 12 (15.8) 
Microcalcifications   8 (10.5) 
 
Total 76 (100) 
 
 
Note. Values in parentheses are percentage. 
 
 
Table 3 Mammographic BIRADS 3 findings and MRI findings.  
 
  
 MRI findings  
                                             ________________________________________________________ 
  
 No abnormal Foci Mass Non-mass 
 enhancement enhancement  enhancement 
 
 
Mammographic BIRADS 3 findings 
 
Noncalcified solid mass (n=56) 19 22 14 1 
Asymmetric density (n=12)   3   4   5 0 
Microcalcifications (n=8)   5   0   3 0 
 
Total 27 (35.5) 26 (34.2)  22 (29.0) 1 (1.3) 
 
 
Note. Values in parentheses are percentage. 




MRI BIRADS category 
In 27 (35.5%) out of 76 patients the breast MRI showed no abnormal enhancement in the 
area corresponding to the mammographic finding and was classified as BIRADS 1. In these 
patients no malignant lesion was seen during at least 2 years study follow-up.  
In 26 (34.2%) out of 76 patients the MRI showed foci in the breast which were classified as 
BIRADS 2 in 21 (80.8%) patients and as BIRADS 3 in 4 (15.4%) patients. The study 
follow-up or pathology of these patients showed no malignancy. In one (3.8%) patient the 
focus was classified as BIRADS 4. This patient had a surgical excision which showed 
normal fibroglandular tissue with pathology.  
Twenty-two (28.9%) patients had a mass enhancement on the MRI. The mass 
enhancements were classified as BIRADS 2 in 4 (18.2%) patients, as BIRADS 3 in 8 
(36.4%) patients, as BIRADS 4 in 5 (22.7%) patients and as BIRADS 5 in 5 (22.7%) 
patients. The 4 BIRADS 2 lesions and 6 out of the 8 BIRADS 3 lesions showed no 
malignancy by study follow-up or pathology. The other masses were malignant by 
pathology. 
In only 1 (1.3%) patient a non-mass enhancement was detected on the MRI. This non-mass 
enhancement was classified as BIRADS 4 and pathology confirmed malignancy (Table 4).  
 
 
Table 4 MRI BIRADS classification and pathologic proven breast cancer.   
 
  
 MRI BIRADS category  
                                                     _________________________________________________________________ 
 
 1 (n=27) 2 (n=25) 3 (n=12) 4 (n=7) 5 (n=5) 
                                                     _________ _________ _________ _________ __________ 
       
Number of breast cancer - + - + - + - + - + 




No abnormal enhanc. (n=27) 27 0 
Foci (n=26) 21 0 4 0 1 0 
Mass enhancement (n=22)   4 0 6 2 0 5 0 5 
Non-mass enhancement (n=1) 0 1 
  






The breast MRI had a sensitivity of 100% (95% CI: 75-100%), specificity of 82.5% (95% 
CI: 71-91%), PPV of 54.2% (95% CI: 33-74%) and NPV of 100% (95% CI: 93-100%). 
ROC analysis revealed an area under the curve (AUC) of 0.98±0.03 (95% CI: 0.85-0.98) 
for breast MRI in the differentiation between benign and malignant mammographic 
BIRADS 3 lesions (Fig. 2). 




Fig. 2 ROC curve for the accuracy of breast MRI to rule out malignancy in mammographic  




In 24 (31.6%) out of 76 patients the final diagnosis was based upon pathology findings of 
the specimen. Eighteen (75.0%) patients underwent a biopsy procedure and 6 (25.0%) 
patients a surgical intervention after the MRI scan. Ten (41.7%) out of these 24 patients had 
invasive ductal carcinoma, 2 (8.2%) patients had an invasive lobular carcinoma and 1 




(4.2%) patient had a metaplastic carcinoma. Normal fibroglandular tissue was found in 10 
(41.7%) patients and a lipoma was found in 1 (4.2%) patient. 
Fifty-two (68.4%) out of 76 patients had a study follow-up of at least 2 years. In these 




According to the guideline of AHRQ and NABON the diagnostic work-up of 
mammographic BIRADS 3 lesions should be a biopsy or a follow-up mammography after 6 
months [4,5]. In our study, we established that there is a role for breast MRI in 
mammographic BIRADS 3 lesions, because a non-invasive imaging modality with high 
NPV can lower the percentage of invasive procedures. The accuracy of the MRI in our 
study is excellent (AUC=0.98) and the NPV is near to 100% (95% CI: 93-100%). 
Therefore, further diagnostic work-up is not needed in patients with a breast MRI classified 
as BIRADS 1 or 2. In our study this is 68.4% (52/76) of the patient group. To our 
knowledge there is only one other report published which deals with the role of MRI in the 
evaluation of probably benign lesions (BIRADS 3) in mammography [9]. In this 
publication a NPV of 100% was reported [9]. Furthermore, other single-center studies, 
which characterize breast lesions independent on BIRADS classification with MRI, have 
shown that the NPVs of breast MRI have been as high as 97% [10,14,15].  
Kuhl [8] on the other hand described that the evidence for the effectiveness of breast MRI 
is relatively weak in helping to solve mammographic interpretations problems, because in a 
multicenter trial of Bluemke et al. the NPV is not high enough to exclude malignancy with 
sufficient confidence in case of an equivocal or suspicious lesion seen at conventional 
imaging [11]. The diagnostic accuracy of MRI was studied in 821 patients with a suspicious 
(BIRADS 4 or 5) mammographic finding (85%) or a suspicious clinical finding with a 
negative or benign conventional work-up (15%) prior to biopsy [11]. MRI had a negative 
predictive value of 85% with cancer missed in 48 of 329 negative MRI examinations. 
Therefore, a biopsy of suspicious mammographic findings (BIRADS 4 or 5) or clinical 
findings based on the absence of a suspicious MRI correlate can not be avoided [11]. 





1998 to 2001 and therefore used now outdated MR equipment. Furthermore, Bluemke et al. 
[11] included microcalcifications of the breast which have negative influence on the NPV. 
There are 3 studies [17-19] which investigated the role of breast MRI in 
microcalcifications. The NPV of these studies varies between 76% and 97% which is in 
accordance with Bluemke results. In our study only 8 patients with mammographic 
BIRADS 3 microcalcifications underwent MRI. If the MRI showed no abnormal 
enhancement no malignant lesion were detected by stereotactic biopsy or 2 years study 
follow-up. However, a definitive conclusion cannot be drawn because our group of 
microcalcifications is too small.  
For mammographic BIRADS 3 lesions it is difficult to decide which work-up strategy 
(biopsy or follow-up after 6 months) is suitable and thus depending on the preference of the 
clinician and the wish of the patient. Therefore, in this group it can be expected that MRI 
has an additional value.  
The majority of mammographic BIRADS 3 findings in our study were noncalcified solid 
masses and asymmetric densities. When these mammographic lesions in our study showed 
no abnormality or foci (lesions smaller than 5 mm) on the MRI, malignancy could be 
excluded. This was in accordance with the publication of Gokalp et al. [9] and  Moy et al. 
[10]. In the report of Gokalp 85% of the 56 mammographic BIRADS 3 lesions were 
noncalcified shaped lesions or asymmetric densitities which were correctly classified as 
benign [9]. 
In the study of Moy et al. [10] 115 breasts MRI’s were used as adjunctive tool and the 
findings were correlated with pathology. The equivocal mammographic findings for which 
MRI was performed were asymmetry without associated microcalcifications (85.2%), 
architectural distortion (10.4%) and change in the appearance of the site of a previous 
benign biopsy finding (4.3%). MRI had a sensitivity of 100%, specificity of 91.7%, NPV of 
100%, PPV of 40.0% and overall accuracy of 92.2%. Moy et al. concluded that breast MRI 
could be an useful adjunctive tool when equivocal findings at conventional mammography 
are asymmetry or architectural distortion [10]. 
In our study the chance of malignancy in the mammographic BIRADS 3 lesions is 
approximately 17%. This is considerably higher than is stated in the guideline of AHRQ 
and NABON (< 2%) [4,5]. It is not likely that the high percentage of malignancy is due to 




the selection of lesions for MRI. Taken into account the total group of 176 BIRADS 3 
lesions, also 17.6% (n=31) of 176 breast lesions were malignant. This result confirms that 
classifying lesions in the BIRADS category 3 is difficult with a very high inter- and 
intraobserver variability in interpretation of mammographic features [20]. Therefore, breast 
MRI can be helpful in cases of mammographic BIRADS 3 lesions. MRI not only has 
shown to give near to 100% (95% CI: 93-100%) prediction of benign lesions, which means 
that no further invasive diagnostic work-up is needed, it also gives a better prediction of 
malignant lesions assessed as BIRADS 3 on mammogram.  
In conclusion, MRI can be used as problem solving modality in noncalcified BIRADS 3 
lesions, because the NPV of MRI is high enough to rule out malignancy with sufficient 
confidence. When the MRI is assessed as BIRADS 1 or 2, no further invasive diagnostic 
assessment is needed. Further multicenter research is needed to verify and implement these 
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Objectives: To evaluate the additional value of computer-aided detection (CAD) in breast 
MRI by assessing radiologists’ accuracy in discriminating benign from malignant breast 
lesions. 
Methods: A literature search was performed with inclusion of relevant studies using a 
commercially available CAD system with automatic colour mapping. Two independent 
researchers assessed the quality of the studies. The accuracy of the radiologists’ 
performance with and without CAD was presented as pooled sensitivity and specificity. 
Results: Of 587 articles, 10 met the inclusion criteria, all of good methodological quality. 
Experienced radiologists reached comparable pooled sensitivity and specificity before and 
after using CAD (sensitivity: without CAD: 89%; 95% CI: 78-94%, with CAD: 89%; 
95%CI: 81-94%) (specificity: without CAD: 86%; 95% CI: 79-91%, with CAD: 82%; 95% 
CI: 76-87%). For residents the pooled sensitivity increased from 72% (95% CI: 62-81%) 
without CAD to 89% (95% CI: 80-94%) with CAD, however, not significantly. Concerning 
specificity, the results were similar (without CAD: 79%; 95% CI: 69-86%, with CAD: 
78%; 95% CI: 69-84%).  
Conclusions: CAD in breast MRI has little influence on the sensitivity and specificity of 
experienced radiologists and therefore their interpretation remains essential. However, 
residents or inexperienced radiologists seem to benefit from CAD concerning breast MRI 
evaluation.  






Dynamic contrast-enhanced Magnetic Resonance Imaging (MRI) is increasingly used to 
evaluate pathological features of the breast. Applications for MRI of the breast include 
diagnostic and screening indications [1-6]. Image analysis is based on the enhancement 
pattern of lesions in dynamic breast MRI and on morphological characteristics [7-9]. Using 
those two criteria for the interpretation of the images, breast MRI has a very high 
sensitivity, which usually exceeds 90% [10-12] and a negative breast MRI shows a 
sufficient high negative predictive value (NPV) (97%) to safely rule out malignancy [13-
15]. However, breast MRI has several limitations, the overall reported specificity varies 
between 67% and 72%, which therefore results in a high number of false-positive results 
[10,12,16]. Furthermore, MRI requires significant time for image acquisition, processing 
and interpretation [17,18]. In order to try to overcome those limitations, Computer Aided 
Detection (CAD) programs for MR imaging of the breast have been developed [18]. In 
general, CAD software was developed to identify suspect features on the image and bring 
them to the attention of the radiologist, in order to decrease false-negative readings [19]. 
However, in breast MRI, most lesions were regarded as having already been detected by the 
radiologist. Therefore, the primary aim to develop CAD for breast MRI was not to identify 
lesions, but to assist the radiologist in determining which lesions are benign and which are 
malignant.  
Computer-aided detection systems automate many processing and analysis functions, which 
would normally have to be performed manually by MRI technologists and radiologists. The 
automated kinetic assessment of CAD generates a colour-coding based on the signal 
intensity voxel changes during the enhancement of the breast tissue. This provides an easier 
way of interpreting the patterns of contrast enhancement (persistent, plateau and washout 
enhancement) across a series of images, which may help identify lesions and their 
likelihood of being malignant.  
The implementation of CAD software may improve the accuracy of breast MRI by 
reducing the number of false-positive diagnoses and by shortening the time needed to 
interpret breast MRI images [17,18,20,21]. Furthermore, a state of the art CAD system 





mammography. This is reflected by a very high sensitivity and NPV for these non-calcified 
breast lesions. 
The purpose of this systematic review and meta-analysis is to assess the radiologists’ 
accuracy in discriminating benign from malignant breast lesions regarding breast MRI with 
and without CAD implementation in terms of sensitivity and specificity. 
 
Materials and Methods 
 
Search strategy 
A computerised search was performed to identify all relevant studies in Medline and 
Embase up to 2010. The following search terms were used in Medline: "Diagnosis, 
Computer-Assisted" [Mesh term] OR “computer-aided-diagnosis” [Text Word] OR 
“computer-aided-detection” [Text Word] OR “computer-aided” [Text Word] OR “CAD” 
[Text Word] OR “three-time-point method” [Text Word] AND "Magnetic Resonance 
Imaging" [Mesh term] OR “Magnetic Resonance Imaging” [Text Word] OR “MRI” [Text 
Word] OR “MR imaging” [Text Word] AND "Breast Neoplasms" [Mesh term] OR “breast 
cancer” [Text Word] OR “mamma carcinoma” [Text Word] OR “malignant breast lesions” 
[Text Word] AND "Sensitivity and Specificity" [Mesh term] OR “specificity OR 
sensitivity” [Text Word]. In Embase the same strategy was used. All languages were 
considered.  
 
Eligibility criteria and study selection 
We searched for studies assessing the value of CAD for a radiologist in the discrimination 
between benign and malignant breast lesions with MRI. Studies were included if the 
following inclusion criteria were met: (1) all patients had undergone breast MRI; (2) a 
commercially available CAD system was used; (3) the study population had benign and 
malignant breast lesions; (4) accuracy, sensitivity, specificity, positive predictive value 
and/or negative predictive value was/were measured or could be derived, and (5) studies 
had to be published with original data in peer-reviewed journals. Studies in which an 
institution-specific CAD system was used were excluded, as well as reviews, editorials and 
case reports. 









Two researchers (MDD, MCJW) independently selected relevant studies based on title and 
abstract or full article. Any discrepancies concerning the study selection were resolved by 
discussion of the full article. The complete search yielded 587 studies. 519 out of 587 
studies were excluded based on the title. After removing duplicates (n=12), 56 studies were 
screened on title and abstract. Twenty-nine studies did not meet the inclusion criteria 
(technical article (n=20), overview (n=8) and case report (n=1)). From the remaining 27 
studies the full article was reviewed. Seventeen studies were excluded because CAD was an 
institution-specific CAD system. Ten studies [20-29] fulfilled our inclusion criteria (Fig. 1). 
Eight studies were in the English language [20-24,26,27,29]; the other 2 were in the 
German Language [25,28]. 
Search result: n= 587 
(319 Pubmed; 268 Embase) 
Excluded based on title (n= 519) 
Papers retrieved for more detailed evaluation (n=56) 
   Selection based on full paper (n=27) 
Excluded (n=29) 
- technical paper: 20 
- overview: 8 
- case report: 1 
Excluded (n=17) 
- institution-specific CAD systems 






Data collection and quality assessment 
The following study descriptives were extracted: population descriptives (age, number of 
patients, number of benign and malignant lesions), study design, type of MRI used, type of 
CAD software used, minimum threshold enhancement used, number of radiologists that 
assessed the MR images with and without the use of CAD and diagnostic accuracy numbers 
(true-positives, false-positives, true-negatives and false-negatives). 
Study quality was assessed independently by the same two observers using the QUADAS 
tool [30,31], disagreement was resolved by arbitration. This evidence-based tool is 
developed specifically to assess the quality of diagnostic accuracy studies and includes 14 
quality items. The 14 items can be scored as “yes”, “no” or “unclear”. The total score can 
range from 0 to 14, in which 14 is the maximum attainable score. 
 
Statistical analysis 
The performance of the radiologist in distinguishing breast lesions on MRI with and 
without the implementation of CAD was assessed. Besides the use of CAD, comparisons 
were made between radiologists with experience in imaging assessment and residents or 
radiologists with no or minor experience. Primary outcome was sensitivity and specificity 
at tumour level. Pooling of data was performed within the bivariate mixed-effects binary 
regression modelling framework. Model specification, estimation and prediction were 
carried out with xtmelogit in STATA. Using the model summary sensitivity and specificity 
were calculated, and a summary ROC curve was drawn (with AUC and confidence 
intervals). A forest plot was generated containing the individual study sensitivities and 
specificities with 95% confidence intervals (CI) and the pooled sensitivity and specificity 
estimates.  
A test for heterogeneity was applied, using the I2 statistic [32]. This statistic calculates the 
percentage of total variation across studies that can be attributed to inter-study 
heterogeneity, ranging from 0 (no heterogeneity) to 100% (all variance due to 
heterogeneity). The presence of publication bias was visually assessed by producing a 
funnel plot. In STATA linear regression was performed of log odds ratios on the inverse 
root of effective sample sizes as a test for funnel plot asymmetry. The log odds ratios are 
defined as the log transformed diagnostic odds ratios, which are needed for the performance 




of linear regression. Publication bias was considered present if there was a significant non-
zero slope coefficient, (p < 0.10), suggesting that only the small studies reporting a high 
sensitivity with CAD had been published, whereas the small studies reporting a lower 
sensitivity had not been published. Data were analysed in SPSS 16.0 (SPSS, Chicago, IL, 




Study descriptives  
The 10 studies included a total of 895 patients (range 29-329) with a total of 1264 breast 
lesions (range 33-469) of which 606 were classified as malignant (range 9-279) and 658 as 
benign (range 22-190) [20-29].  
In 5 [23,24,26-28] studies a selection was made of patients with suspect findings based on 
mammography and ultrasound examinations. In the other 5 studies [20-22,25,29] patients 
with a suspect lesion on MRI were included. One of these 5 studies retrospectively searched 
the database of an ongoing MRI screening study of patients at high risk of breast cancer for 
BIRADS 3-5 lesions that were detected with MRI [22], and 2 studies included lesions that 
were not palpable and were not visible on mammography or ultrasound [20,21]. In all 10 
studies histology was used as the gold standard. In 4 studies a follow-up MRI after 6 or 24 
months was performed [23,25,28,29]; in the case of positive findings biopsy provided 
further histological assessment.  
Mean study quality was 12.6, ranging from 10 to 14. Four studies were of maximum quality 
(Table 1) [20,21,26,27]. 
 
CAD systems 
In all 10 studies the CAD systems (CADstream, DynaCAD, Fulltime point, 3-Time-Point 
Method and CAD-Gaea) incorporated precontrast medium (unenhanced) images and 2  
(immediate and delayed) or all postcontrast medium (enhanced) images [20-29]. The CAD 
systems compared pixel intensity values on the precontrast medium and immediated 
postcontrast medium series. If a pixel value increased above a user-specified minimum 




Table 1 Study characteristics of the 10 included studies (SD standard deviation, NR not reported, P prospective, R retrospective, c consecutive, TB 
tumour-based). 
 
Study (author, ref., No. of Study Quality Mean age No. of  No. of  No. of Type of MRI CAD 
year of publication) patients design score (SD or range) lesions malignant  benign analysis system 
 
Arazi [22] 2009 53 R, c 13 47 (26-68) 56 22 34 TB 1.5T CAD-Gaea 
     
Meeuwis [27] 2009 65 R, c 14 49 (29-71) 71 49 22 TB 3.0T CADstream 
 
Baltzer [23] 2009 51 R, c 12 51 (13) 90 46 44 TB 1.5T DynaCAD  
 
Baltzer [24] 2009  329 P, c 13 53 (15-83) 469 279 190 TB 1.5T DynaCAD 
 
Veltman [29] 2009 NR R,c 11 NR 52 25 27 TB 1.5T 3-Time-Point  
 
Renz [28] 2008  48 P, c 11 51 (31) 88 43 45 TB 1.5T DynaCAD 
           Full-time point 
 
Hauth [25] 2008  137 R 10 NR 183 61 122 TB 1.5T 3-Time-Point  
 
Williams [21] 2006 126 R, c  14 52 (27-86) 154 41 113 TB 1.5T CADstream 
 
Lehman [20] 2005 29 R, c  14  NR 33 9 24 TB 1.5T CADstream 
 
Kelcz [26] 2002 57 P, c 14 52 (31-80) 68 31 37 TB 1.5T 3-Time-Point  
 
 




regarded as meeting threshold enhancement. Once a pixel was identified as enhancing 
above the established threshold, the CAD systems compared pixel signal intensity values on 
the immediate and delayed postcontrast medium series to indicate washout enhancement, 
plateau enhancement or persistent enhancement. A specific colour or colour intensity was 
assigned to each pixel for different types of tissue enhancement. The end result of all CAD 
systems was a colour overlay on each MRI slice indicating regions of significant 
enhancement and providing details about enhancement type and extent.  
  
CAD threshold enhancement  
Six [20-24,27] studies analysed the presence or absence of “threshold enhancement” at 
different minimum thresholds. Lehman et al. [20], Williams et al. [21] and Meeuwis et al. 
[27] used the CAD system CADstream. The sensitivity at the minimum thresholds of 50, 
80% and 100% remained the same. The specificity increased at higher minimum 
thresholds. The study by Meeuwis et al. [27] showed a higher specificity than the other two 
studies. In the studies by Baltzer et al. [23,24] DynaCAD was used. In these studies, the  
 
 
Table 2 The sensitivity and specificity of a CAD system using the presence or absence of lesion 
enhancement at the user-specified minimum thresholds.  
 
Study MRI CAD  No. of MRI assessed Sensitivity Specificity
  system lesions by using 
 
Arazi  [22] 1.5T CAD-Gaea 56 Threshold 50% 100% 0%  
  Threshold 80% 95.5% 14.7%  
  Threshold 100% 72.7% 44.1%  
Baltzer [23] 1.5T DynaCAD  90 Threshold < 50% 100% 0% 
  Threshold 50%-100% 84.8% 45.4% 
  Threshold > 100% 52.1% 72.7% 
Baltzer [24] 1.5T DynaCAD 469 Threshold < 50% 100% 0% 
   Threshold 50%-100% 86.4% 53.2% 
   Threshold > 100% 52.0% 83.7% 
Meeuwis [27]  3.0T CADstream 71 Threshold 50% 97.9% 86.4% 
  Threshold 100% 97.9% 90.9% 
Williams [21] 1.5T  CADstream 154 Threshold 50% 92.7% 8.9% 
   Threshold 100% 92.7% 23.0% 
Lehman [20] 1.5T CADstream 33 Threshold 50% 100% 25.0% 
   Threshold 80% 100% 33.0% 
   Threshold 100% 100% 50.0% 
   
  
Table 3 The performance of radiologists and residents in breast MRI diagnosis in terms of sensitivity and specificity with and without the use of a CAD 
system, specified for type of CAD and MRI system, number of lesions, and experience (RAD radiologist RES resident). 
 
Study MRI CAD system No. of lesions MRI assessed by using Experience Sensitivity Specificity  
 
Arazi  [22] 1.5T CAD-Gaea 56 CAD+RAD 5 years 73.0% 56.0% 
Meeuwis [27]  3.0T CADstream 71 CAD+RAD1 > 5 years 88.5% 75.0% 
  71 CAD+RAD2 > 5 years 92.3% 87.5% 
  71 CAD+RES1 6 months 88.5% 93.8% 
  71 CAD+RES2 0 months 84.6% 81.3% 
  42 RAD (manual)a  84.6% 68.8% 
Baltzer [23] 1.5T DynaCAD 90 CAD+RAD 1-3 years 80.4% 72.7% 
Baltzer [24] 1.5T DynaCAD 469 CAD+RAD >300 MRIs 78.8% 73.2% 
   469 RAD (manual)a 75.3% 76.3% 
  469 RAD (visual)b  72.4% 77.4%  
Renz [28]  1.5T DynaCAD 88 CAD+RAD1 > 500 MRIs 100% 86.7% 
   88 CAD+RAD2 > 500 MRIs 95.3% 93.3% 
   88  CAD+RAD3 < 50 MRIs 90.7% 73.3% 
  Full-time point 88 CAD+RAD1 100% 84.4% 
   88 CAD+RAD2 95.3% 91.1% 
   88 CAD+RAD3 100% 66.7% 
   88 RAD1 (visual)b 97.7% 84.4% 
   88 RAD2 (visual)b 93.0% 93.3% 
   88 RAD3 (visual)b 86.0% 77.8% 
Veltman [29] 1.5T 3-Time-point 52 CAD+RES1 0 months 80% 78% 
   52 CAD+RES2 3 months 80% 81% 
   52 CAD+RES3 5 years 80% 85% 
   52 CAD+RAD4 15 years 80% 78% 
   52 RES1 (manual)a 68% 67% 
   52 RES2 (manual)a 52% 81% 
   52 RES3 (manual)a 72% 85% 
   52 RAD4 (manual)a 84% 85%  
Hauth [25] 1.5T 3-Time-point  183 CAD+RAD 3 years 60.7% 83.6%  
Kelcz [26] 1.5T 3-Time-point 68 CAD+RAD >500 MRIs 87.0% 84.0%  
 
a
 Manual: manual curve analysis by using the region of interest (ROI) method. 
b
 Visual: visual evaluation of contrast enhancement. 
  
 





sensitivity decreased and the specificity increased at higher minimum thresholds. CAD-
Gaea [22] had the same results as DynaCAD with respect to sensitivity and specificity, 
although CAD-Gaea had a lower level of specificity. Meeuwis et al. [27], using 
CADstream, reported the highest sensitivity and specificity (Table 2). 
 
Radiologist with or without CAD  
In 8 out of 10 studies [22-29] the sensitivity and specificity of the radiologist or resident in 
assessing MR images with the use of CAD were measured (Table 3). The enhancement 
thresholds used were set up individually according to the radiologist’s preference. 
Furthermore, in 4 [24,27-29] out of these 8 studies the sensitivity and specificity of the 
radiologist or resident was also calculated without the use CAD. In these four studies the 
radiologists or residents assessed the MR images as visual evaluation of contrast 





Fig. 3 Summary ROC curve regarding the studies of radiologists and residents using a CAD system.  




method [24,27-29]. The pooled sensitivity and specificity of radiologists and residents 
assessing breast lesions on MRI without the implementation of CAD was 82% (95% CI: 
72-90%) and 81% (95% CI: 74-87%), respectively. With CAD implementation they 
attained higher sensitivity scores (sensitivity: 89%, 95% CI: 83-93%; specificity: 81%, 95% 
CI: 76-85%) (Fig. 2). The sROC curve showed an AUC of 0.89 (Fig. 3). In 3 studies 
differentiation was made between radiologists with experience and residents with no or 
minimal experience [27-29]. The experience of those radiologists varied from 5 to 15 years 
(or > 500 MRIs). Residents had no more than 6 months (or < 50 MRIs) breast MRI 
experience. After stratification, the experienced radiologists showed a comparable pooled 
sensitivity of 89% with (95% CI: 81-94%) and without (sensitivity: 89%; 95% CI: 78-94%) 
CAD implementation. The pooled specificity of 86% (95% CI: 79-91%) decreased to 82% 
(95% CI: 76-87%) with CAD. Residents or radiologists with less experience showed a 
pooled sensitivity of 72% (95% CI: 62-81%) and a pooled specificity of 79% (95% CI: 69-
86%) when assessing breast lesions on MRI without CAD. With the use of CAD, their 
sensitivity increased to 89% (95% CI: 80-94%), whereas their specificity remained 
comparable (specificity: 78%; 95% CI: 69-84%) (Table 4). 
 
 
Table 4 Results of pooled sensitivity and specificity (95% CI) of the radiologist in assessing breast 
lesions on MRI with and without the use of a CAD system in general, stratified for experienced 
radiologists and residents with no or less experience (RANDOM effects model). 
 
Outcome or subgroup    Studiesa      Sensitivity (95% CI) Specificity (95%CI)              
 
Radiologist no CAD, general 4b 82% (72%-90%) 81% (74%-87%) 
Radiologist with CAD, general 8c 89% (83%-93%) 81% (76%-85%) 
Experienced radiologist no CAD 4b 89% (78%-94%) 86% (79%-91%) 
Experienced radiologist with CAD 8c 89% (81%-94%) 82% (76%-87%) 
Residents no CAD 3d 72% (62%-81%) 79% (69%-86%) 




 In studies in which more than one radiologist/resident (blinded) assessed the images, the pooled calculation was  
  based on all relevant radiologists in that study. 
b
 Meeuwis [27], Baltzer [24], Renz [28], Veltman [29]. 
c
 Arazi-Kleinmann [22] Meeuwis [27], Baltzer [23], Baltzer [24], Renz [28], Veltman [29], Hauth [25], Kelcz [26]. 
d





Analyses of heterogeneity 
Moderate to substantial heterogeneity was observed among the eight studies exploring the 
sensitivity and specificity of radiologists assessing MR images with and without the 
implementation of CAD (sensitivity: no CAD: I2: 78%, p<0.0001, with CAD: I2: 80%, 
p<0.0001; specificity: no CAD: I2: 46%, p=0.007, with CAD: I2: 55%, p=0.002). After 
stratification of radiologists with experience and residents with no or minimal experience, 
heterogeneity did not change for experienced radiologists (sensitivity: no CAD: I2: 79%, 
p<0.0001, with CAD: I2: 83%, p<0.0001), and residents (sensitivity: no CAD: I2: 79%, 
p=0.009; with CAD: I2: 64%, p=0.02). Concerning specificity, heterogeneity dropped to 




Fig. 4 Funnel plot with log odds ratios on the inverse root of effective sample sizes for visualisation 
of publication bias. 




CAD: specificity: I2: 62%, p=0.01; residents without CAD: specificity: I2: 33%, p=0.22; 
residents with CAD: specificity: I2: 24%, p=0.26). Because of heterogeneity and possible 
unmeasured variance at the study level a random-effects model was used to obtain all 
pooled estimates, as this model interprets the available data with more caution and uses 
broad confidence intervals. 
 
Assessment publication bias 
A non-significant non-zero slope coefficient (p-value = 0.16) indicated that there was no 
evidence of publication bias (Fig. 4). This suggests that we most likely did not miss studies 




This meta-analysis shows that the pooled sensitivity and specificity of the experienced 
radiologist for the assessment of breast lesions with MRI remains comparable with the 
implementation of CAD. Residents or radiologists with less experience seem to attain a 
higher sensitivity with CAD implementation, although not significant. 
All selected studies were of high quality, so it is likely that the quality of the studies did not 
have a significant impact on the results of the meta-analysis. Furthermore, there was no 
evidence of publication bias and therefore it is not expected that the meta-analysis 
overestimates the effect of CAD evaluation.  
The ten studies used different indications for breast MRI and there was a wide variation in 
the number and tissue type of lesions selected [20-29]. This resulted in the greater 
heterogeneity. Therefore, we used a random-effects model that interprets the results with 
more caution. Furthermore, there was an indication of selection bias. In all studies the 
radiologists only assessed MRIs with lesions (≥ BIRADS 2) and discriminated between 
benign and malignant. This selection increased the prevalence of breast malignancy in the 
study population compared with the target population. The lesion selection could have 
influenced the performance of the radiologist. 
Six studies analysed the influence of the presence or absence of “threshold enhancement” at 





resulted in the highest sensitivity and specificity. This result could be explained by the fact 
that a 3.0T MRI system was applied, which has a better performance than the 1.5T MRI 
scanner which was used in the other studies.  
With CADstream the sensitivity at a higher enhancement threshold remained the same, i.e. 
the same malignant lesions enhanced at the 50%, 80% and 100% thresholds [20]. The 
remaining false-negative enhancing malignant lesions showed no enhancement with 
CADstream due to a noise filtering process leading to failure of automatic analysis of small 
areas of enhancement [21,27]. The specificity of CADstream increased at higher 
enhancement thresholds, which means that at a higher threshold benign lesions did not 
enhance [20]. Therefore, absence of lesion enhancement at higher thresholds helps to 
improve the discrimination between benign and malignant lesions. In comparison to the 
study by Meeuwis et al. [27], the low specificity of the study by Williams et al. [21] is most 
likely due to the high prevalence (n= 22/71 versus n= 113/154) and the large tissue type 
variation of benign lesions.  
With the DynaCAD software the specificity performance was analogous to that of the 
CADstream software. The sensitivity of DynaCAD however, decreased at higher threshold 
enhancements, not visualising all malignant enhancements, resulting in false-negative 
lesions [23].  
Residents or radiologists with no or less experience achieved a higher sensitivity when they 
were accompanied by a CAD system for discrimination between breast lesions on MRI. 
The change in sensitivity after using CAD was not significant. Nevertheless, a considerable 
increase could be seen (sensitivity from 72%; 95% CI: 62-81% to 89%; 95% CI: 80-94%). 
This increase could be a result of the fact that CAD brings more enhancing lesions to the 
attention of the resident or inexperienced radiologist. Therefore, it seems that they benefit 
from CAD when assessing breast lesions with MRI. However, more research must be 
conducted to verify these results.   
The performance of the experienced radiologists showed a non-significant decrease in 
specificity from 86% (95% CI: 79-91%) without CAD to 82% (95% CI: 76-87%) with 
CAD. A clarification for this observation could be that CAD systems are only based on the 
enhancement dynamic, without regarding the morphology of the lesion. As a consequence, 
the use of CAD could lead to a higher number of enhancing lesions, part of which could be 




assigned as benign on the basis of morphology. The experienced radiologists can be 
mislead by the enhancement pattern of CAD, resulting in a decrease in specificity. 
Therefore, it is important that experienced radiologists are aware of this.   
In conclusion, concerning the assessment of MR images CAD has little influence on the 
sensitivity and specificity of the performance of radiologists experienced in breast MRI 
diagnosis. Therefore, breast MRI interpretation by radiologists remains essential. Residents 
or radiologists with less experience seem to benefit from a CAD system when performing 




1.  DeMartini W, Lehman C. A review of current evidence-based clinical applications for breast 
magnetic resonance imaging. Top Magn Reson Imaging 2008;19(3):143-150. 
2.  DeMartini W, Lehman C, Partridge S. Breast MRI for cancer detection and characterization: a 
review of evidence-based clinical applications. Acad Radiol 2008; 15(4):408-416. 
3.  Kuhl CK. Current status of breast MR imaging. Part 2. Clinical applications. Radiology 2007; 
244(3):672-691. 
4.  Mann RM, Kuhl CK, Kinkel K, Boetes C.Breast MRI: guidelines from the European Society 
of Breast Imaging. Eur Radiol 2008; 18(7):1307-1318. 
5.  Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008; 
26(5):703-711. 
6.  Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of 
breast cancer. Radiology 2001; 220(1):13-30. 
7.  Macura KJ, Ouwerkerk R, Jacobs MA, Bluemke DA. Patterns of enhancement on breast MR 
images: interpretation and imaging pitfalls. Radiographics 2006; 26(6):1719-1734. 
8.  Schnall MD, Blume J, Bluemke DA, et al. Diagnostic architectural and dynamic features at 
breast MR imaging: multicenter study. Radiology 2006; 238(1):42-53. 
9. Szabo BK, Aspelin P, Wiberg MK, Bone B. Dynamic MR imaging of the breast. Analysis of 
kinetic and morphologic diagnostic criteria. Acta Radiol 2003; 44(4):379-386. 
10.  Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior 
to biopsy. JAMA 2004; 292(22):2735-2742. 






12.  Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of 
MR imaging in the diagnosis of breast lesions. Radiology 2008; 246(1):116-124. 
13.  Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women 
proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. 
Radiology 2000; 215(1):267-279. 
14.  Moy L, Elias K, Patel V, et al. Is breast MRI helpful in the evaluation of inconclusive 
mammographic findings?  AJR 2009; 193(4):986-993. 
15.  Vassiou K, Kanavou T, Vlychou M, et al. Characterization of breast lesions with CE-MR 
multimodal morphological and kinetic analysis: comparison with conventional mammography 
and high-resolution ultrasound. Eur J Radiol 2009; 70(1):69-76. 
16.  Hrung JM, Sonnad SS, Schwartz JS, Langlotz CP. Accuracy of MR imaging in the work-up of 
suspicious breast lesions: a diagnostic meta-analysis. Acad Radiol 1999; 6(7):387-397. 
17.  Rothenberg RM. Computer-aided detection of malignancy with magnetic resonance imaging 
of the breast. Technol Eval Cent Asses Program Exec Summ 2006; 21(4):1-3. 
18.  Wood C. Computer Aided Detection (CAD) for breast MRI. Technol Cancer Res Treat 2005; 
4(1):49-53. 
19.  Castellino RA. Computer aided detection (CAD): an overview. Cancer Imaging 2005; 
5(1):17-19. 
20.  Lehman CD, Peacock S, DeMartini WB, Chen X . A new automated software system to 
evaluate breast MR examinations: improved specificity without decreased sensitivity. AJR 
2006; 187(1):51-56. 
21.  Williams TC, DeMartini WB, Partridge SC, Peacock S, Lehman CD. Breast MR imaging: 
computer-aided evaluation program for discriminating benign from malignant lesions. 
Radiology 2007; 244(1):94-103. 
22.  Arazi-Kleinman T, Causer PA, Jong RA, Hill K, Warner E. Can breast MRI computer-aided 
detection (CAD) improve radiologist accuracy for lesions detected at MRI screening and 
recommended for biopsy in a high-risk population? Clin Radiol 2009; 64(12):1166-1174. 
23.  Baltzer PA, Renz DM, Kullnig PE, Gajda M, Camara O, Kaiser WA. Application of 
computer-aided diagnosis (CAD) in MR-mammography (MRM): do we really need whole 
lesion time curve distribution analysis? Acad Radiol 2009; 16(4):435-442. 
24.  Baltzer PA, Freiberg C, Beger S, et al. Clinical MR-mammography: are computer-assisted 
methods superior to visual or manual measurements for curve type analysis? A systematic 
approach. Acad Radiol 2009; 16(9):1070-1076. 




25.  Hauth EA, Jaeger H, Maderwald S, Muhler A, Kimmig R, Forsting M. Quantitative 
parametric analysis of contrast-enhanced lesions in dynamic MR mammography. Radiologe 
2008; 48(6):593-600. 
26.  Kelcz F, Furman-Haran E, Grobgeld D, Degani H. Clinical testing of high-spatial-resolution 
parametric contrast-enhanced MR imaging of the breast. AJR 2002; 179(6):1485-1492. 
27.  Meeuwis C, van de Ven SM, Stapper G, et al. Computer-aided detection (CAD) for breast 
MRI: evaluation of efficacy at 3.0 T. Eur Radiol 2009; 20(3):522-528. 
28.  Renz DM, Baltzer PA, Kullnig PE, et al. Clinical value of computer-assisted analysis in MR 
mammography. A comparison between two systems and three observers with different levels 
of experience. Rofo 2008; 180(11):968-976. 
29.  Veltman J, Mann RM, Meijer FJ, et al. The additional value of three time point color coding 
in dynamic contrast-enhanced MRI of the breast for inexperienced and experienced readers. 
Eur J Radiol 2010; 74(3):514-518. 
30.  Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J.The development of QUADAS: a 
tool for the quality assessment of studies of diagnostic accuracy included in systematic 
reviews. BMC Med Res Methodol 2003; 3:25. 
31.  Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of 
QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res 
Methodol 2006; 6:9. 
32.  Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. 
BMJ 2003; 327(7414):557-560. 
33.  Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-






Quantitative multivoxel proton  
chemical shift imaging of the breast 
 
Paul E. Sijens 
Monique D. Dorrius 
Peter Kappert 
Paul Baron 
Ruud M. Pijnappel 
Matthijs Oudkerk 
 





Abstract   
 
The study of focal pathology by single voxel magnetic resonance spectroscopy (MRS) is 
hampered by the impossibility to study tissue heterogeneity or compare the metabolite 
signals in breast lesion directly to those in unaffected tissue. Multivoxel MRS studies while 
potentially allowing for truly quantitative tissue characterization, have up to now also been 
far from quantitative with, for example, the signal-to-noise ratio of the choline (Cho) signal 
serving as measure of tumor activity. Shown in this study is that in a standard clinical 
setting with a regular 1.5T magnetic resonance scanner, it is possible to perform 
quantitative multivoxel MR spectroscopy. With the use of literature values for the T1 and 
T2 relaxation times of Cho and water in fibroglandular breast tissue and tumors one can 
determine the concentrations of Cho in different tumor compartments and surrounding 
tissues in two brief multivoxel MRS measurements. This opens excellent perspectives to 
quantitative diagnostic and follow-up studies of focal pathology such as lesions suspected 
of breast cancer. 






Proton magnetic resonance spectroscopy (MRS) studies of the human breast published to 
date have been either single voxel [1-16] or multivoxel investigations [15,17-20]. With 
some exceptions [3,7,16], the metabolites detected by single voxel MRS were documented 
in, at best, a semi-quantitative fashion such as assessment of the signal-to noise ratio in the 
choline (Cho) peak, peak visibility, or non-referenced arbitrary peak area units. 
Furthermore, the study of focal pathology by single voxel MRS will always be hampered 
by the impossibility to study tissue heterogeneity or compare the metabolite signals in a 
breast lesion directly to those in unaffected tissue. Multivoxel MRS studies while 
potentially allowing for truly quantitative tissue characterization, have up to now also been 
far from quantitative with the use of the Cho signal-to-noise ratio as measure of tumor 
activity [15,17-20]. This is a rather arbitrary and irreproducible parameter affected by 
multiple factors such as the B0 and B1 field distributions and patient movement. The 
purpose of this study is to present a quantitative multivoxel MRS method for the 
examination and metabolic mapping of pathology in the human breast.  
 
Materials and Methods 
 
Magnetic resonance imaging (MRI) and proton (1H) MRS were performed at 1.5T using a 
Magnetom Avanto system with a body RF coil for excitation and a commercially available 
circularly polarized breast array receiver coil equipped with automatic tuning and electronic 
decoupling (Siemens, Erlangen, Germany). The MRI protocol included transverse and 
sagittal T2 weighted fast spin-echo series covering both breasts (TR/TE 4500/102), 
performed without distortion correction to optimise MRS planning. After acquisition of the 
MRS series, T1-weighted MRI (FLASH 2D, 10º pulse angle, TR/TE 4.2/1.3) was 
performed in the transverse direction and repeated after Gd-contrast agent (0.2 mmol/kg, 
Dotarem; Guerbet, Villepinte, France) administration.  
The multivoxel MRS technique used was an institutional modification of two-dimensional 
chemical shift imaging (CSI) point-resolved spectroscopy (PRESS) double spin-echo [21,22] 





optimized 180◦ pulse [23]. Two-dimensional CSI of the breast was performed twice, first 
without suppression of the water and fat signals to serve as a reference measurement and 
subsequently with suppression of the water and fat signals to be able to detect Cho. The field of 
view was 8x8 cm to roughly cover the transverse cross section of the examined breast, 
subdivided into 144 phase encode steps to yield voxels of 0.67x0.67x1 cm at the used slice 
thickness of 1 cm. In this hybrid CSI technique the volume of interest was smaller than the 
field of view (3x3x1 cm) in order to end up with essentially measuring the watery part of the 
breast (glandular breast tissue, pathology). Unwanted water and lipid signals were suppressed 
by band selective inversion with gradient dephasing [24,25]. This was realized by 
implementing a frequency selective 180◦ RF pulse surrounded by two crusher gradient pulses 
of opposite signs, with PRESS excitation to suppress both water and lipid signals using a 
minimum phase bandstop pulse designed to pass Cho to N-acetylaspartate resonances and 
suppress water and lipid signals [25]. Six additional nine-lobe sinc outer volume suppression 
pulses were applied before excitation, resulting in 6 outer volume suppression slabs of at least 3 
cm thickness each on all sides of the volume of interest. Further reduction of the water signal 
was achieved by chemical shift-selective presaturation [26] and by water reference post-
processing (next paragraph). 512 data points were acquired at a band width of 1250 Hz 
resulting in a data acquisition time of 410 ms. In the first measurement without suppression of 
any signal the repetition time (TR) and echo time (TE) were set at 1500 ms and 30 ms, 
respectively [27]. The TE was kept small in order to minimize loss of water and fat peak 
intensities due to T2 relaxation and the TR was set at 1500 ms in order to limit the acquisition 
time to 4:46 min. The second measurement was performed at the same TR and at a longer TE 
(135 ms) in order to be able to presaturate the water signal and to reduce the impact of residual 
fat signals on the spectral baseline (acquisition time 4:46 min).  
In the postprocessing the 12x12 phase encode steps were interpolated into a 16x16 matrix, i.e. 
voxels appearing as 0.5x0.5x1 cm3. The number of peaks fitted included the chemical shift 
ranges restricted to 3.15-3.3 ppm for the N(CH3)3 group of Cho, 2.9-3.1 for the NCH3 group of 
creatine (Cr), 4.5-5.0 ppm for water, and 1.0-1.5 ppm for the main resonance of fat (-CH2-). 
Using standardized postprocessing protocols, the raw data were processed automatically, 
allowing for operator-idependent quantifications. The postprocessing protocol for the water 
and fat suppressed series consisted of water reference processing, hanning filtering (width 




700 ms, center 0 ms), zero filling from 512 to 1024 data points, Fourier transformation, 
polynomial baseline correction (with the above peak ranges excluded),  phase correction 
and curve fitting to Gaussian line shapes using the standard scanner software.  
The concentrations of the metabolites Cho and Cr were calculated from the relative peak 
areas of the resonances of Cho (N(CH3)3 at 3.23 ppm) or Cr (NCH3 at 3.01 ppm), denoted 
SM, and water (H2O at 4.7 ppm) using the following formula: 
 
[M] = SM/SH2O x TWC x 1/MwH2O x nH2O/nM x T1satH2O/T1satM x T2satH2O/T2satM (1) 
 
In order to report concentrations in a molar (moles per liter of tissue volume) unit, literature 
values were adapted for the tissue water contents (TWC) of voxels containing breast tumor 
tissue, 82% [28] and fibroglandular breast tissue, 65.3% [29]; nH2O is 2, nCr is 3 and nCho is 
9. MwH2O stands for the molecule weight of water. [For simplicity and in order to reduce 
reliance on literature values, one might want to leave out the TWC correction and report 
metabolite concentrations per liter of water. One then obtains tumor and fibroglandular 
tissue metabolite levels that are (1/0.82*100%=) 22% higher and (1/0.653*100%=) 53% 
higher than the values reported here]. 
Any difference in receiver gain or scaling factor between the subsequent MRS 
measurements was corrected for. Furthermore, the processing of all MRS data was repeated 
without water reference processing to make certain that no lipid artifacts were introduced 
near the frequencies of Cho end Cr. 
The T1-saturation factors and T2-saturation factors for water, Cr and Cho were calculated 
using the following formulas: 
 
T1sat = 1 – exp (-TR/T1)        (2) 
 
T2sat = exp (-TE/T2)        (3) 
 
For the T1 of water in fibroglandular breast tissue we used the means of the values 
published by Graham et al. [29] (1301 ms) and Rakow-Penner at al. [30] (1333 ms), i.e. 
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Fig. 1 Volume of interest (36 voxels of 0.25 cm3 each) centered on an adenocarcinoma in the left 
breast of a 53 year old patient (a-c) and a spectral map showing intense water and minor fat peaks in 
the lesion (d). After application of water and fat suppression, an intense Cho peak is detected in tumor 
(e) as compared with no signal in adipose tissue (f). The tumor shows up as hyperintense in the Cho 
map (g). After administration of Gd-contrast, tumor and surrounding areas are hyperintense on T1-
weighted MRI (h). 




1513 ms, respectively, published by Baik et al. [12]. Lacking literature values, we used the 
T1 of Cho in normal brain tissue (1240 ms) [31] as the value to be expected in 
fibroglandular tissue. For the T2 of water in fibroglandular tissue we used the means of the 
values published by Graham et al. [29] (40 ms) and Rakow-Penner at al. [30] (58 ms), 
i.e.49 ms.  For the T2 of water in breast tumor, we adapted the value of 97 ms published by 
Baik et al. [12]. For the T2 of Cho in breast tumor, we used the means of the values 
published by Bakken (340 ms) [32] and Baik (269 ms) [12], i.e. 305 ms. Lacking literature 
values, we used the T2 of Cho in normal brain tissue (311 ms) [31] as the value to be 
expected in fibroglandular tissue. For the T1 and T2 of the N-CH3 group of Cr (3.01 ppm), 
detected in fibroglandular tissue only, the relaxation times published for normal brain tissue 




The feasibility of the CSI method is demonstrated in two patients (examined by MRI/MRS 
with informed consent) whose pathologies were confirmed by biopsy. For a 53 year old 
patient suffering from an invasive ductal carcinoma of the left breast, figure 1 shows the 




a b c 
Fig. 2 Volume of interest (36 voxels of 0.25 cm3 each) centered on fibroglandular tissue in the left 
breast of a 32 year old control subject with CSI spectral map showing intense water and minor fat 
peaks in most voxels (a). After application of water and fat suppression, minor Cho and Cr peaks are 
detected in the fibroglandular tissue (b). A similar result is obtained in the same subject reexamined 
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Fig. 3 Volume of interest (36 voxels of 0.25 cm3 each) centered on an invasive ductal carcinoma in 
the left breast of a 38 years old patient (a-c) and a spectral map showing intense water and minor fat 
peaks in the lesion (d). After application of water and fat suppression, an intense Cho peak is detected 
in tumor (e). The tumor shows up as hyperintense in the Cho map (f). After administration of Gd-
contrast, the tumor is amongst those areas that are hyperintense on T1 weighted MRI (g). 




map of the first CSI measurement without any suppression of the water and fat signals 
shows intense water (left side, 4.7 ppm) and minor fat peaks (right side 1.3 ppm) for each 
voxel containing lesion (Fig.1d). After application of water and fat suppression, in 4 tumor 
voxels an intense Cho peak is detected at 3.23 ppm (Fig.1e) as compared with no signal in 9 
voxels containing adipose tissue (Fig.1f) and the minor Cho and Cr signals in the 
fibroglandular tissue of a healthy control subject aged 32 years examined twice (Fig.2). The 
tumor shows up as hyperintense in the metabolic map of Cho (Fig.1g). At 10 minutes 
afterthe administration of Gd-contrast agent, tumor and surrounding areas are hyperintense 
on T1 weighted MRI acquired with a water-only excitation pulse (Fig.1h). Figure 3 shows 
similar results for an invasive ductal carcinoma in a patient of 38 years old. 
Using equations 1 to 3 and the relaxation times cited in Materials and Methods, the 
following concentrations are calculated: In the 4 tumor voxels of the first example (Fig.1e) 
the mean concentration of Cho is 2.8 mM. The highest level encountered in one of the 4 
tumor voxels is 4.1 mM. Mere noise was measured in the adipose tissue from the same 
volume of interest. In the fibroglandular breast tissue of the healthy younger woman 
serving as control (Fig.2) Cho and Cr concentrations of 0.3 and 0.8 mM, respectively, are 
calculated at the first examination (Fig.2b) and of 0.6 and 0.8 mM at another examination 
performed 4 weeks later (Fig.2c). The mean Cho concentration in the second tumor 




In this study, we have shown that in a standard clinical setting with use of a regular 1.5T 
MR scanner, it is possible to perform quantitative multivoxel MRS. With the use of 
literature values for the T1 and T2 relaxation times of Cho, Cr and water in fibroglandular 
breast tissue and tumors, one can determine the concentrations of metabolites in different 
tumor compartments and surrounding tissues in two brief multivoxel MRS measurements. 
As is always the case in quantitative MRS, one has to rely on multiple assumptions. 
However, the great advantage of converting metabolite peak areas into concentrations 
(mM) is that true comparisons can be made, between different patients and pathologic 





breast cancer. This opens excellent perspectives to quantitative diagnostic and follow-up 
studies of focal pathology such as lesions suspected of breast cancer. 
Breast tumor levels of Cho, widely accepted as prime tumor marker in proton MRS [33] 
near 2 mM have been observed by single voxel MRS using the water signal as internal 
reference [7,16]. Considering, also, that in brain metastases of breast cancer Cho 
concentrations of up to 4 mM have been observed [34], the tumor Cho concentration of up 
to 4.1 mM observed here, exceeding that in fibroglandular tissue by one order of 
magnitude, appears in agreement. Noted here is that in normal brain, the level of Cho also 
is rather high, 1.72 mM in white matter tissue and 1.54 mM in gray matter tissue [35]. It 
should be noted that these two patients were the first ones with confirmed breast cancer 
examined at our institution. Different levels may be detected in subsequent patients. We 
have thus shown that multivoxel CSI is able to detect tumor Cho at low concentrations. In 
our CSI method, as in any quantitative MRS approach of tumor characterization, a 
limitation is the use of literature T1 and T2 values for determining the saturation factors 
affecting quantification. It is obvious that T1 and T2 varies between tumor types and 
patients and may even change significantly during therapy [36]. Our healthy volunteer data, 
yielding fibroglandular Cho contents of 0.3 and 0.6 mM in the same person reexamined 4 
weeks apart, indicate that the reproducibility of  breast CSI measured Cho content is in the 
order of 0.3 mM. 
We believe that the current widespread practice of single voxel or non-quantitative 
multivoxel MRS examination of breast cancer is inadequate. Quantitative multivoxel MRS 
can now be performed in less than 10 minutes, even when using a daily routine 1.5T MRI 
system, and should therefore be used for the examination and metabolic mapping of 
pathology in the human breast.  
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Purpose: To determine the optimal cutoff of choline (Cho) concentration in quantitative 
multivoxel magnetic resonance (MR) spectroscopic data to safely prove benignancy in 
breast lesions. 
Materials and Methods: The study was institutional review board approved, and informed 
consent was obtained from each patient. Between July 2009 and July 2010, multivoxel MR 
spectroscopy was performed in 24 consecutive patients with 25 breast lesions assessed as 
Breast Imaging Reporting and Data System 3 or 4 and larger than 1 cm in diameter at 
mammography. Two-dimensional point-resolved spatially localized spectroscopy chemical 
shift imaging was first performed without signal suppression (repetition time msec/echo 
time msec, 1500/30) as reference measurement and was performed subsequently with 
suppression of water and fat signals (1500/135) to detect Cho. Differences in mean and 
highest Cho concentration in the breast lesions were tested for significance by using the 
independent sample t test. The final diagnosis was confirmed with pathologic findings.  
Results: Fourteen of 25 breast lesions were malignant. The mean Cho concentration varied 
between 0.3 and 1.3 mmol/L (0.84 mmol/L ± 0.32 [standard deviation]) in benign lesions 
and between 1.3 and 9.5 mmol/L (3.10 mmol/L ± 2.21) in malignant lesions. The highest 
Cho concentrations in benign and malignant lesions were 0.4–1.5 mmol/L (1.19 mmol/L ± 
0.33) and 1.7–11.8 mmol/L (4.08 mmol/L ± 2.81), respectively. Mean and highest Cho 
concentrations in benign and malignant breast lesions differed significantly (P = .02 for 
both). 
Conclusions: The study, in a relatively small patient population, shows that quantitative 
multivoxel MR spectroscopy can be applied to exclude benign breast lesions from further 
invasive diagnostic work-up with the implementation of a Cho concentration of 1.5 mmol/L 
or lower as a cutoff. Further larger studies will be needed to confirm these results. 






In vivo proton magnetic resonance (MR) spectroscopy is a noninvasive technique that can 
provide tumor metabolic information. MR spectroscopy has been increasingly applied for 
the evaluation of breast lesions and therapy response monitoring [1-28]. The diagnostic 
value of MR spectroscopy is generally based on the detection of elevated levels of choline-
containing compounds (Cho), which are markers of an active malignant breast tumor.  
MR spectroscopy can be performed as single- [1-21] or multivoxel [22-28] technique. The 
single-voxel technique has limitations in terms of lesion coverage, which may affect the 
sensitivity of the assessment of Cho from just one voxel in view of tumor heterogeneity 
[22,26]. Multivoxel MR spectroscopy, referred to as spectroscopic imaging or chemical 
shift imaging, acquires spectroscopic information from a large volume of interest 
subdivided into an array of voxels measured in a single measurement [22-28]. Therefore, 
the multivoxel MR spectroscopic technique is suitable for analyzing the regional 
distribution of tumor metabolites and studying tissue heterogeneity. Another advantage of 
multivoxel MR spectroscopy is the possibility of metabolic mapping of breast lesions [26]. 
Several single-voxel MR spectroscopic studies conducted at 1.5T have shown the results of 
the single-voxel technique for differentiating between malignant and benign breast lesions 
on the of the detection of Cho (peak visibility or Cho signal-to-noise ratio) [1-21]. 
However, in studies Cho signals were also detected in benign lesions and normal breast 
tissues [3-5,11,13]. Therefore, the presence of a Cho-related peak in breast MR 
spectroscopy is not sufficient for a noninvasive diagnosis of malignancy. Quantification of 
the peak of Cho is required to determine the accurate levels of Cho. 
Although, with the possibility of mapping Cho distributions, the multivoxel MR 
spectroscopic technique is potentially suited for performing truly quantitative tissue 
characterization, previous multivoxel MR spectroscopic studies have up to now been far 
from quantitative, with the use of the Cho signal-to-noise ratio as measure of tumor activity 
[22,24,25,28]. One recent study [26] presented a quantitative multivoxel MR spectroscopic 
method for the examination and metabolic mapping of disease in the human breast. With 
the use of literature values for  T1 and T2 relaxation times of Cho and water in 





different tumor compartments and surrounding tissues in two brief multivoxel MR 
spectroscopic measurements [26]. The purpose of this study is to determine the optimal 
cutoff of Cho concentration in quantitative multivoxel MR spectroscopic data to exclude 
benign lesions from further invasive diagnostic work-up. 
 
Materials and Methods 
 
Patient population 
This prospective study was conducted between July 2009 and July 2010 at the University 
Medical Center Groningen. Twenty-four consecutive patients (mean age, 48.4 years; age 
range, 32–69 years) with 25 breast lesions (irrespective whether the lesion was palpable or 
not) assessed as Breast Imaging Reporting and Data System (BI-RADS) 3 or 4 and larger 
than 1 cm in diameter at mammography underwent multivoxel MR spectroscopy. Patients 
were excluded if there was a history of breast cancer, hematoma of the breast, or previous 
breast surgery including breast implants. Referral indication for mammography was 
recorded. The final diagnosis of the breast lesions was confirmed by using histologic or 
cytologic findings of the breast lesion. Tissue samples were obtained by using 
ultrasonographically (US) guided fine-needle aspiration biopsy (n = 3), US-guided core 
biopsy (n = 21), or MR-guided vacuum-assisted core biopsy (n = 1). This study was 
approved by the Medical Ethical Committee of the University Medical Center Groningen. 
Informed consent was obtained from each patient prior to the study. The clinicians and 
patients were not informed of the results from MR spectroscopy. 
 
MR imaging and MR spectroscopy 
MR imaging was performed at 1.5 T by using a whole-body MR imager (Magnetom 
Avanto; Siemens Medical Solutions, Erlangen, Germany) with a body radiofrequency coil 
for excitation and a commercially available circularly polarized bilateral breast phased-
array receiver coil with automatic tuning and electronic decoupling (Siemens Medical 
Solutions), with the patient in the prone position. The MR imaging protocol included 
diffusion-weighted imaging with b values of 0, 50, 200, 500, 800, and 1000 sec/mm2 and 
transverse T2-weighted turbo spin-echo imaging (repetition time msec/echo time msec, 




4500/102; field of view, 340 mm; section thickness, 4 mm). A transverse and sagittal T2-
weighted fast spin-echo series covering both breasts (4500/102) was performed without 
distortion correction for MR spectroscopy planning. For the spectroscopic imaging 
technique, the MR spectroscopic protocol of Sijens et al. [26] was used. This protocol 
included two-dimensional chemical shift imaging with double-spin-echo point-resolved 
spatially localized spectroscopy with phase-encoding gradients between the section-
selective 90° pulse and the first section-selective optimized 180° pulse. Two-dimensional 
chemical shift imaging of the breast was performed twice, first without suppression of 
water and fat signals (1500/30) to serve as a reference measurement. The echo time was 
kept small to minimize loss of water and fat peak intensities due to T2 relaxation, and the 
repetition time was set at 1500 msec to limit the acquisition time to 4 minutes 46 seconds. 
The second measurement was with suppression of water and fat signals (1500/135) to be 
able to detect Cho. The same repetition time and a longer echo time (135 msec) were used 
to be able to presaturate the water signal and to reduce the effect of residual fat signals on 
the spectral baseline (acquisition time, 4 minutes 46 seconds). The total MR spectroscopic 
acquisition time therefore was less than 10 minutes.  
The field of view was 8 × 8 cm to roughly cover the transverse cross section of the examined 
breast and was subdivided into 144 phase-encode steps at the used section thickness of 1 cm. In 
this hybrid chemical shift imaging technique, the volume of interest, on which the automated 
adjustments of B0 field (shimming), frequency, transmitter gain, and receiver attenuation were 
performed, was smaller than the field of view (3 × 3 × 1 cm) to end up with essentially 
measuring the watery part of the breast (glandular breast tissue and/or disease). The bandwidth 
was 1300 Hz (corresponding with a section-select gradient of approximately 1 mT/m), which 
caused a chemical shift displacement error of 1.5 mm between the metabolic maps of Cho and 
water. In our data analysis, this small effect was not corrected for. Unwanted water and lipid 
signals were suppressed with band-selective inversion with gradient dephasing [26].  
No intravenous contrast material at MR imaging was administered to the patients prior to 
the MR spectroscopy to prevent possible interference of metal chelate with the detectability 
of Cho [29,30]. Contrast material was administered afterward, but, in this study, the results 





us from evaluating the incremental benefit of the incorporation of MR spectroscopy into the 
MR imaging diagnostics of breast cancer. 
 
Data analysis 
The MR spectroscopic measurements were performed in breast lesions larger than 1 cm in 
diameter at mammography that were localized on diffusion- and T2-weighted images; the 
results of MR spectroscopy then were projected on the transverse T2-weighted MR imaging 
series. A standard software package (Syngo; Siemens) was used for postprocessing MR 
spectroscopic data. The 12 × 12 phase-encode steps were interpolated into a 16 × 16 matrix 
(ie, voxels appearing as 0.5 × 0.5 × 1 cm). The number of peaks fitted included the 
chemical shift ranges restricted to 2.9–3.1 ppm for creatine, 3.1–3.4 ppm for Cho, 4.5–5.0 
ppm for water, and 1.0–1.5 ppm for the main resonance of fat (-CH2-). By using 
standardized postprocessing protocols, the raw data were processed automatically, allowing 
for operator-independent quantifications. To further minimize the amount of arbitrary 
operator input, no use was made of the possibility of retrospective voxel shifting.  
The concentration of the metabolite Cho was calculated from the relative peak areas of the 
resonances of Cho (N(CH3)3 at 3.23 ppm), denoted SM, and water (H2O at 4.7 ppm) by 
using the following equation: 
 
[Cho] = SM/SH2O x TWC x 1/MwH2O x nH2O/nM x T1satH2O/T1satM x T2satH2O/T2satM  
 
where S is signal, M is metabolic Cho, TWC is tissue water content, Mw is molecular 
weight, n is number of hydrogen nuclei, and sat is saturation. To make the method robust, 
concentrations were reported in a molar unit (ie, in moles per liter of voxel volume 
regardless of the composition, such as tumor, extracellular fluids, glandular tissue). For this 
purpose, the water signal (peak area) in the lesion voxels is considered to be equal to 91 
mol/L, that is, the literature value for the tissue water content of voxels containing breast 
tumor tissue, or 82% [28] of the molar proton content of pure water (2 · 1000/18 = 111 
mol/L); nH2O is 2 and nM is 9. The T1 and T2 saturation factors for water and Cho were 
calculated by using literature values for T1 and T2 relaxation times of water and Cho as 
described by Sijens et al [26].  




Lesion voxels were defined as voxels matching the lesion location at MR imaging and 
having a water signal larger than the fat signal. The above procedure of deriving lesion Cho 
concentrations from the unsuppressed water signal thus led to values corrected for partial 
volume effect of adipose tissue (characterized by intense lipid signals and very little water, 
resulting in decreasing water reference signal in proportion to the adipose fraction). Note 
that the metabolic maps of Cho, as shown in the figures, are not corrected for partial 
volume effect, which means that these reflect the distribution of Cho signals over the entire 
volume of interest regardless of the spatial distributions of water and fat, rather than the 
water-fraction Cho concentrations as could be calculated by using the respective water 
fractions on a voxel-by-voxel basis.  
 
Statistical analysis 
The mean and standard deviation of the Cho peak, the mean Cho concentration, and the 
highest Cho concentration of all benign and malignant lesions were calculated. Differences 
between benign and malignant breast lesions concerning the Cho measurements were tested 
for significance by using the independent sample t test. A P value less than .05 was 
considered to indicate a statistically significant difference. Data were analyzed with 




The indication for undergoing mammographic examination was a palpable breast lesion in 
16 (67%) patients. In three (13%) patients, a suspicious (nonpalpable) lesion was found at 
screening mammography performed by the Dutch National Breast Cancer Screening 
Program. Three (13%) patients were screened outside the National Screening Program 
because they were at high risk for breast cancer at young age, and two (8%) patients had an 









Fig. 1 Transverse MR image shows volume of interest (36 voxels of 0.25 cm3 each) centered on an 
invasive ductal carcinoma in the left breast of  38-year-old woman (a).Spectral map shows intense 
water and minor fat peaks in the lesion (b). After application of water and fat suppression, an intens 
Cho peak is detected in the tumor , as shown on spectra. MR images are inset (c). Cho map shows 




Twenty-five breast lesions exceeding 1 cm on the mammogram were assessed. (One patient 
had a mammographic BI-RADS 3 lesion and a BI-RADS 4 lesion in the left breast.) Ten 
(40%) of 25 breast lesions were classified as BI-RADS 3, and 15 (60%) were classified as 
BI-RADS 4 on the mammogram. One (10%) of 10 mammographic BI-RADS 3 lesions was 
malignant, and 13 (87%) of 15 BI-RADS 4 lesions were malignant (Table 1). The size of 




the benign lesions as seen at MR imaging varied between 10 and 21 mm. For malignant 
lesions, the size was between 10 and 58 mm. 
 
 
Table 1 Mammographic BI-RADS classification and disease in 25 breast lesions. 
 
BI-RADS Classification and Disease Size on MR image (mm) Biopsy method  
 
BI-RADS 3 (n=10) 
 Fibroadenoma (n=4) 13, 12, 10, 10 US-guided core biopsy 
 No malignant cells (n=3) 12.5, 14, 10 Fine-needle aspiration biopsy 
 Fibrosis with apocrine metaplasie (n=1) 13 MR-guided vacuum-assisted  
  core biopsy 
 Lobular hyperplasia without atypia (n=1) 19 US-guided core biopsy  
 Invasive ductal carcinoma (n=1) 10 US-guided core biopsy 
 
BI-RADS 4 (n=15) 
 Invasive ductal carcinoma (n=10) 33, 29, 24, 17, 27 US-guided core biopsy 
  34, 15, 16, 21, 41 
 Invasive lobular carcinoma (n=2) 15, 20 US-guided core biopsy 
 Metaplastic carcinoma (n=1) 11 US-guided core biopsy 
 Fibroadenoma (n=1) 15 US-guided core biopsy 




Multivoxel MR spectroscopy 
The volume of interest (36 voxels of 0.25 cm3 each after postprocessing) was centered on 
the breast lesion (Fig. 1, 2). For malignant lesions, after application of water and fat 
suppression, Cho peak was intense in voxels containing malignant tumor and was 
negligible outside the lesion (Fig. 1c, 1d). For benign lesions, the Cho peak was not nearly 
as prominent as in malignant tumors, although, as seen on the metabolic map, still exceeds 
the levels of Cho in voxels outside the lesion (Fig. 2c, 2d).  
The number of voxels used for calculating the mean and the highest Cho concentration in 
25 breast lesions varied from 2 to 7 voxels, with an average of 4 voxels. The Cho peak of 
14 malignant and 11 benign breast lesions was detected in the spectrum between 3.08 and 
3.23 ppm (3.18 ppm ± 0.05 [standard deviation]) and 3.14 and 3.34 ppm (3.24 ppm ± 0.07) 









Fig. 2 Transverse MR image shows volume of interest (36 voxels of 0.25 cm3 each) centered on a 
benign fibroadenoma in the left breast of 44-year- old woman (a).Spectral map shows intense water 
and minor fat peaks in most of the volume of interest (b). After application of water and fat 
suppression, a small Cho peak is detected (also some creatine [Cr}) in the lesion, as shown on spectra. 
MR images are inset (c). Cho map shows small Cho peak as hyperintense (d).  
 
 
For the 14 malignant breast lesions, the mean Cho concentration varied between 1.3 and 9.5 
mmol/L (3.10 mmol/L ± 2.21), and the highest Cho concentration varied between 1.7 and 
11.8 mmol/L (4.08 mmol/L ± 2.81). For the 11 invasive ductal carcinomas, the highest Cho 
concentration ranged from 1.7 to 6.8 mmol/L, and for two invasive lobular carcinomas, it 
ranged from 2.3 to 11.8 mmol/L. The metaplastic carcinoma had a highest Cho 
concentration of 3.9 mmol/L (Table 2).  




The mean Cho concentration of the 11 benign breast lesions was between 0.3 and 1.3 
mmol/L (0.84 mmol/L ± 0.32), and the highest Cho concentration was between 0.4 and 1.5 
mmol/L (1.19 mmol/L ± 0.33). For the five fibroadenomas, the highest Cho concentration 
ranged from 0.4 to 1.3 mmol/L. For the three breast lesions that showed no malignant cells 
after fine-needle aspiration biopsy, the highest Cho concentration varied between 0.8 and 
1.5 mmol/L. The lobular hyperplasia and epithelial hyperplasia lesions had a highest Cho 
concentration of 1.0 and 1.4 mmol/L, respectively. Fibrosis with apocrine metaplasia 
showed a highest Cho concentration of 1.5 mmol/L (Table 2).  
 
 
Table 2 Number of voxels, Cho peak, and mean and highest Cho concentration for 14 malignant and 
11 benign breast lesions. 
 
Disease No. of  Cho peak  Mean Cho Highest Cho 
 Voxels (ppm) conc (mmol/l) conc (mmol/l) 
 
Malignant lesions (n=14) 
 Invasive ductal carcinoma (n=11) 2 3.14 1.6 1.7 
 2 3.23 1.3 1.8 
 2 3.20 1.6 1.8 
 3 3.14 2.1 2.2 
 4 3.23 1.4 2.4 
 3 3.14 1.7 2.5 
 4 3.23 2.8 4.1 
 4 3.20 4.1 4.4 
 6 3.20 3.4 4.6 
 7 3.18 4.7 6.8 
 4 3.23 4.9 6.8 
 Invasive lobular carcinoma (n=2) 2 3.14 2.0 2.3 
 5 3.08 9.5 11.8 
 Metaplastic carcinoma (n=1) 7 3.18 2.4 3.9 
 
Benign lesions (n=11) 
 Fibroadenoma (n=5) 6 3.32 0.3 0.4 
 6 3.17 0.9 1.3 
 2 3.16 1.0 1.3 
 2 3.22 1.1 1.3 
 2 3.17 1.3 1.3 
 No malignant cells (n=3) 4 3.31 0.4 0.8 
 2 3.27 0.9 1.3 
 4 3.34 0.8 1.5 
 Fibrosis with apocrine metaplasie (n=1) 4 3.30 0.6 1.5 
 Lobular hyperplasia without atypia (n=1) 4 3.20 0.7 1.0 






There was a similar significant difference between benign and malignant lesions for the 
mean and the highest Cho concentration (P = .02 for both) (Table 3). Furthermore, with 
regard to the highest Cho concentration, there was no overlap between the values for benign 
(0.4–1.5 mmol/L) and malignant (1.7–11.8 mmol/L) lesions. With regard to the mean 
benign and malignant Cho concentration, the ranges overlapped at 1.3 mmol/L (0.3–1.3 vs 
1.3–9.5 mmol/L, respectively). 
 
 
Table 3 The mean and the standard deviation for Cho peak and mean and highest Cho concentration 
in benign and malignant lesions. 
 
Measurement Benign lesions (n=11) Malignant lesions (n=14) P-value 
 
Cho peak (ppm) 3.24 ± 0.07 3.18 ± 0.05 .04 
Mean Cho concentration (mmol/L) 0.84 ± 0.32 3.10 ± 2.21 .02 






MR spectroscopy is a noninvasive technique that has not yet fulfilled its potential of being 
able to help reliably differentiate between benign and malignant breast lesions. Most of the 
studies published to date used single-voxel MR spectroscopic method [1-21]. The 
remainder are multivoxel studies, preferable in oncology, because those studies are able to 
provide improved metabolic assessment, given the inherent tissue heterogeneity, owing to 
improved sampling approaches with high spectral resolution and large spatial coverage. 
Qualitative or semiquantitative multivoxel measurements were previously used for the 
detection of Cho (i.e. detectibility or Cho signal-to-noise ratio) [22-25,27,28]. In our study, 
a recently published multivoxel MR spectroscopic method based on quantitative 
measurement was implemented [26]. We provided a strong indication that the lesion Cho 
concentration in millimolars as a cutoff, namely 1.5 mmol/L, can be applied to exclude 
benign breast lesions, such as fibroadenomas, from further invasive diagnostic work-up. 




However, with respect to the small sample size, larger studies are needed to verify these 
results.  
A limitation was the larger than 1 cm lesion size that we required for study inclusion. With 
MRI systems of 3.0T or higher, the expected gain in signal-to-noise ratio should enable 
implementation of our MR spectroscopic method at higher spatial resolution (smaller 
voxels enabling the detection of smaller tumors).  
There have been single-voxel MR spectroscopic studies  proposing quantification of Cho 
peak by using an external reference method with known concentrations or an internal 
reference method [2,5,13,21]. With the use of an external reference method, there is no 
correction for partial volume of adipose tissue in the voxel [21]. Alternatively, using water 
as an internal reference automatically compensates for partial volume effect and does not 
require separate calibration experiments [2,5]. A limitation was the assumption that water 
content does not change during varying pathological conditions [2,5]. Moreover, the 
variation of water content may be quite large, depending on the placement of the voxel, but 
internal referencing may correct for this. Whereas these single-voxel studies [2,5,13,21] 
have demonstrated their use for quantification of Cho concentrations in breast lesions, 
single-voxel MR spectroscopic technique will always be hampered by a lack of direct 
comparison of the metabolite signals in breast lesions with those in unaffected tissue. 
Furthermore, there is a loss of sensitivity of the assessment of Cho from just one single 
voxel in view of tumor heterogeneity [22,26]. 
The high spectral resolution and large spatial coverage of multivoxel technique make it 
advantageous over the single-voxel technique. The external and internal reference methods 
that had been used in single-voxel techniques are not practical for the multivoxel technique 
because of the requirement of a long imaging time to measure correction factors (eg, 
receiver gain, partial volume effects, and T1 and T2 relaxation times, etc.). Furthermore, a 
good reference acquisition and good water and fat suppression are needed for 
quantification, which may not be achieved given the field inhomogeneity across the large 
chemical shift imaging grid [22]. In our study, the latter problem was overcome by 
measuring a volume of interest considerably smaller than the entire chemical shift imaging 
grid (3x3x1 cm of 8x8x1 cm). Nevertheless, the method applied here also has technical 





under-sampling, whole breast coverage in acceptable imaging times and quantification. At 
the modest volume of interest used in this study, B0 inhomogeneity and B1 inhomogeneity 
did not present problems, but with large chemical shift imaging volumes, the effectivity of 
water and fat suppression may be compromised. The wings or sidebands of the much larger 
residual water and lipids signals could lead to ambiguous detection of the Cho signal 
because of the overlap. We acknowledge that for 8 of 25 lesions with only 2 out of 36 
voxels (Table 2) the chemical shift imaging approach cannot be substantially different from 
a single-voxel approach. The fact remains that in our quantitative multivoxel MR 
spectroscopic study, improved methods for water and fat suppression [26] have enhanced 
the detectability of Cho and thus facilitated the measurements of its mean and highest 
concentration in both benign and malignant lesions. 
In previous chemical shift imaging studies of breast tumors [22,24,25], the peak intensity of 
Cho was measured in the lesion and expressed relative to the background noise level 
(signal-to-noise ratio), which is a far from quantitative measurement of Cho because signal-
to-noise ratio depends on multiple unpredictable factors that vary among examinations. In 
the study of Beak et al. [22]  which yielded the highest accuracy, at the optimal cutoff of 
Cho, signal-to-noise ratio greater than 3.2, the number of false-negative cases was five [22]. 
The present study indicates that with the highest Cho concentration of 1.5 mmol/L or lower 
as a cutoff, rather than a signal-to-noise ratio, no malignant lesions were falsely scored as 
benign. Nevertheless, our quantitative approach also has drawbacks, including assumptions 
as to the water content of the lesion and its relaxation times, factors affecting the precision, 
and accuracy of the Cho concentrations. 
In our study, a significant difference between benign and malignant lesions is found both in 
the mean (P = .02) and the highest (P = .02) Cho concentration. However, this statistical 
analysis was based on comparisons between groups of lesions. For the diagnosis of an 
individual patient, the highest Cho concentration is advised rather than the mean Cho 
concentration, because in the former data set there was no overlap between the outcome of 
benign and malignant lesions at 0.4–1.5 mmol/L versus 1.7–11.8 mmol/L, respectively. 
Another argument for the highest Cho concentration method is that, especially in large 
tumors covered by multiple MR spectroscopic voxels, the maximum Cho level encountered 
in a cross section is a more objective measure than the lesion average. The latter is 




determined by the arbitrary setting of the borders of the lesion and decisions as to whether 
to include necrotic and cystic areas.  
Furthermore, there is a tendency of chemical shifts of Cho in malignant and benign breast 
lesions to be different (P = .04). Stanwell et al. [14] and Stanwell and Mountford [27] 
suggested that the spectrum obtained in a malignant breast lesion has a resonance at 3.23 
ppm, interpreted as representative of phosphocholine, whereas the spectrum obtained in 
fibroadenoma has a resonance at frequency of 3.28 ppm because of differences in the 
biochemical contents of the nonmalignant tissue (eg, in the individual or combined levels of 
glycerophosphocholine, taurine, or myoinositol) [14,27]. However, in our data, overlap 
between the position of Cho peak in the spectrum for malignant and benign lesions was 
large, 3.08-3.23 ppm versus 3.14-3.34 ppm, respectively. This indicates that there is no 
specific frequency of the Cho peak in the spectrum related to malignancy.  
A limitation in our present study was that we did not assess the results of dynamic contrast-
enhanced MR imaging, which prohibited us from evaluating the incremental benefit of the 
incorporation of MR spectroscopy into the MR imaging diagnostics of breast cancer.  
In conclusion, the finding in this feasibility study that breast lesions with a volume of 1 cm3 
or greater and a Cho concentration of 1.5 mmol/L or lower are benign indicates that, in this 
patient group, multivoxel MR spectroscopy can potentially replace invasive diagnostic 
work-up. However, further research is needed to verify the cutoff of 1.5 mmol/L in a 




1.  Baek HM, Chen JH, Nalcioglu O, Su MY. Proton MR spectroscopy for monitoring early 
treatment response of breast cancer to neo-adjuvant chemotherapy. Ann.Oncol. 2008; 
19(5):1022-1024. 
2.  Baik HM, Su MY, Yu H, Mehta R, Nalcioglu O. Quantification of choline-containing 
compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal 
reference at 1.5 T. MAGMA. 2006; 19(2):96-104. 
3.  Bartella L, Morris EA, Dershaw DD, et al. Proton MR spectroscopy with choline peak as 
malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary 





4.  Bartella L, Thakur SB, Morris EA, et al. Enhancing nonmass lesions in the breast: evaluation 
with proton (1H) MR spectroscopy. Radiology 2007; 245(1):80-87. 
5.  Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the 
breast with 1H MR spectroscopy. Magn Reson.Med. 2003; 50(6):1134-1143. 
6.  Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions 
with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer 
Res.Treat. 2001; 68(1):45-54. 
7.  Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast 
tumors using a dedicated double breast coil. J.Magn Reson.Imaging 1998; 8(6):1191-1197. 
8.  Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast 
malignancy: diagnostic MR protocol for improved specificity. Radiology 2004; 232(2):585-
591. 
9.  Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume 
localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally 
advanced breast cancer. Br.J.Cancer 2001; 84(8):1016-1022. 
10.  Joe BN, Chen VY, Salibi N, Fuangtharntip P, Hildebolt CF, Bae KT. Evaluation of 1H-
magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. 
Invest Radiol. 2005; 40(7):405-411. 
11.  Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human 
breast tissues with in vivo (1)H MR spectroscopy. J.Magn Reson.Imaging 1999; 10(2):159-
164. 
12.  Lee J, Yamaguchi T, Abe A, et al. Clinical evaluation of choline measurement by proton MR 
spectroscopy in patients with malignant tumors. Radiat.Med. 2004; 22(3):148-154. 
13.  Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization 
with proton MR spectroscopy. Radiology 1998; 209(1):269-275. 
14.  Stanwell P, Gluch L, Clark D, et al. Specificity of choline metabolites for in vivo diagnosis of 
breast cancer using 1H MRS at 1.5 T. Eur.Radiol. 2005; 15(5):1037-1043. 
15.  Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-
enhanced in vivo proton MR spectroscopy--initial results. Radiology 2001; 220(1):40-46. 
16.  Baek HM, Chen JH, Nie K, et al. Predicting pathologic response to neoadjuvant chemotherapy 
in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 2009; 
251(3):653-662. 




17.  Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F. In vivo proton MR 
spectroscopy of the breast using the total choline peak integral as a marker of malignancy. 
AJR 2009; 192(6):1608-1617. 
18.  Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are 
they useful tools for characterizing breast lesions before biopsy? AJR  2009; 193(3):840-849. 
19.  Tse GM, Cheung HS, Pang LM, et al. Characterization of lesions of the breast with proton 
MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR 
2003; 181(5):1267-1272. 
20.  Yeung DK, Yang WT, Tse GM. Breast cancer: in vivo proton MR spectroscopy in the 
characterization of histopathologic subtypes and preliminary observations in axillary node 
metastases. Radiology 2002; 225(1):190-197. 
21.  Bakken IJ, Gribbestad IS, Singstad TE, Kvistad KA. External standard method for the in vivo 
quantification of choline-containing compounds in breast tumors by proton MR spectroscopy 
at 1.5 Tesla. Magn Reson.Med. 2001; 46(1):189-192. 
22.  Baek HM, Chen JH, Yu HJ, Mehta R, Nalcioglu O, Su MY. Detection of choline signal in 
human breast lesions with chemical-shift imaging. J.Magn Reson.Imaging 2008; 27(5):1114-
1121. 
23.  Geraghty PR, van den Bosch MA, Spielman DM, et al. MRI and (1)H MRS of the breast: 
presence of a choline peak as malignancy marker is related to K21 value of the tumor in 
patients with invasive ductal carcinoma. Breast J. 2008; 14(6):574-580. 
24.  Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic 
resonance spectroscopic imaging of human breast cancer: a preliminary study. J.Magn 
Reson.Imaging 2004; 19(1):68-75. 
25.  Jacobs MA, Barker PB, Argani P, Ouwerkerk R, Bhujwalla ZM, Bluemke DA. Combined 
dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. 
J.Magn Reson.Imaging 2005; 21(1):23-28. 
26.  Sijens PE, Dorrius MD, Kappert P, Baron P, Pijnappel RM, Oudkerk M. Quantitative 
multivoxel proton chemical shift imaging of the breast. Magn Reson.Imaging 2010; 
28(3):314-319. 
27.  Stanwell P, Mountford C. In vivo proton MR spectroscopy of the breast. Radiographics 2007; 
27 Suppl 1:S253-S266. 
28.  Su MY, Baik HM, Yu HJ, Chen JH, Mehta RS, Nalcioglu O. Comparison of choline and 
pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and 





29.  Sijens PE, van den Bent MJ, Nowak PJ, van Dijk P, Oudkerk M. 1H chemical shift imaging 
reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn 
Reson.Med. 1997 ; 37(2):222-225. 
30.  Sijens PE, Oudkerk M, van Dijk P, Levendag PC, Vecht CJ. 1H MR spectroscopy monitoring 
of changes in choline peak area and line shape after Gd-contrast administration. Magn 









The added value of  
quantitative multi-voxel MR spectroscopy  
in breast Magnetic Resonance Imaging 
 
Monique D. Dorrius 
Ruud M. Pijnappel 




Paul E. Sijens 
 







Purpose: To determine whether quantitative multivoxel MR spectroscopy improves the 
accuracy of MRI in the assessment of breast lesions.  
Materials and Methods: Twenty-five consecutive patients with 26 breast lesions ≥1 cm 
assessed as BI-RADS 3 or 4 with mammography underwent quantitative multivoxel MR 
spectroscopy and contrast-enhanced MRI. The MR spectroscopic technique used was 2D-
CSI with PRESS to measure the choline (Cho) concentration as calculated from the 
unsuppressed water signal. ROC analysis was used to quantify the diagnostic accuracy of 
MRI and MR spectroscopy in the assessment of breast lesions.  
Results: Mean Cho concentrations in 26 breast lesions classified by MRI as BI-RADS 2 
(n=5), 3 (n=8), 4 (n=5) and 5 (n=8) were 1.16±0.43SD, 1.43±0.47SD, 2.98±2.15SD and 
4.94±3.10SD mM, respectively. Two of the BI-RADS 3 lesions and all BI-RADS 4 and  5 
lesions were malignant on pathology and had Cho concentrations between 1.7-11.8mM 
(4.03±2.72SD), which was significantly higher (P = .01) than the Cho in the 11 benign 
lesions (all BI-RADS 2 lesions and 6 out of 8 BI-RADS 3 lesions) of  0.4-1.5mM 
(1.19±0.33SD). Furthermore, Cho concentrations between the benign and malignant breast 
lesions in BI-RADS 3 category differed (P = .01). The accuracy of multivoxel MR 
spectroscopy added to the breast MRI BI-RADS classification (AUC = 1.00) exceeded the 
accuracy of MRI alone (AUC = 0.96±0.03). 
Conclusions: These preliminary data indicate that multivoxel MR spectroscopy improves 
the accuracy of MRI in the assessment of breast lesions, especially in BI-RADS 3 category. 
If further research confirms that breast lesions with a volume ≥1cm3 and Cho 
concentrations up to 1.5mM are benign, this could prevent invasive procedures in the 
diagnostic work-up. 






Breast Magnetic Resonance Imaging (MRI) is emerging as an important diagnostic 
modality. With the use of morphological characteristics and kinetic analysis of breast 
lesions on MRI, the sensitivity of breast MRI approaches 90% whereas the overall 
specificity of breast MRI varies between 67% and 72% [1-3]. Although the negative 
predictive value (NPV) of MRI in breast cancer is the highest of all imaging techniques 
(97%) [4-6], meaning that in most cases a negative breast MRI can safely rule out 
malignancy, breast MRI alone is still not the perfect modality.  
The fourth edition of the Breast Imaging Reporting and Data System (BI-RADS) Atlas 
includes a new lexicon for breast MRI that promotes the standardization of lesion 
descriptors and assessment categories [7]. This lexicon is based on the results of 
International Working Group on Breast MRI and the American College of Radiology 
(ACR) Breast MRI Lexicon Committee and includes a BI-RADS 3 assessment category [7-
10]. The suggested work-up of these probably benign findings is a short-time interval 
follow-up or biopsy. At this moment most approaches are intuitive [11,12]. It can be 
expected that the majority of patients thus referred for biopsy have a benign lesion.  
In addition to morphologic and kinetic analysis, metabolic information is considered useful 
for the assessment of breast lesions. A promising approach to clarify the precise nature 
(benign or malignant) of a lesion is the use of a non-invasive MRI method which is referred 
to as MR spectroscopy [13,14]. The diagnostic value of MR spectroscopy is typically based 
on the detection of elevated levels of choline (Cho) compounds. MR spectroscopic studies 
of the breast have been either single-voxel [13-33] or multivoxel [34-40] investigations. 
The single-voxel technique has limitations in terms of lesion coverage. The general practice 
of including either the entire lesion or just its center in the voxel, may result in dilution of 
the elevated Cho levels in vital malignant tumor by contributing necrotic and cystic tumor 
areas with low Cho levels, resulting in false negatives [34,38].  
The multivoxel MR spectroscopic technique or chemical-shift imaging (CSI) acquires 
spectroscopic information from a large volume of interest subdivided into an array of 
voxels measured in a single measurement and has potential for performing truly 





only detected in malignant breast lesion but also in benign breast lesions and normal 
fibroglandular tissue [13,14,17,23,25,36]. Recently, multivoxel MR spectroscopy was used 
for measurement of the Cho concentrations encountered in breast lesions [38].  
The purpose of this study is to determine whether the Cho level measured by quantitative 
multivoxel MR spectroscopy can increase the accuracy of contrast-enhanced MRI in the 
assessment of breast lesions. 
 
Materials and Methods 
 
Patient population 
This prospective study was conducted between July 2009 and July 2010 at the University 
Medical Center Groningen and was approved by the Medical Ethical Committee of the 
University of Groningen. Informed consent was obtained form each patient prior to the 
study. 
Twenty-five consecutive patients (mean age: 48.7 years, age range: 32-69) with 26 breast 
lesions ≥ 1cm assessed as BI-RADS 3 or BI-RADS 4 with mammography underwent 
multivoxel MR spectroscopy and contrast-enhanced MRI. Patients were excluded if there 
was a history of breast cancer, a hematoma of the breast or previous breast surgery 
including breast implants. The final diagnosis of the breast lesions was based on cytology 
or histology, considered as the gold standard. Tissue samples were obtained by ultrasound-
guided fine needle aspiration biopsy (FNAB) (n=3), ultrasound-guided core biopsy (n=5), 
MR-guided vacuum-assisted core biopsy (n=1) or surgery (n=17).  
 
MR imaging  
MR scans were performed at 1.5T using a whole body MRI system (Avanto; Siemens 
Medical Solutions, Erlangen, Germany) with a dedicated bilateral breast coil and the patient 
in prone position. The standard MRI protocol included diffusion weighted imaging (DWI) 
with b-values 0, 50, 200, 500, 800 and 1000. A T2 turbo spin echo (Repetition Time (TR)/ 
Echo Time (TE) 4500/102ms, FOV 340mm and slice thickness 4mm) was performed in the 
transversal plane. A T1 weighted three-dimensional (3D) DynaVIEWS sequence 
(TR/TE/FA 4.17ms/1.29ms/10deg, FOV 340mm and slice thickness 0.97mm, totally 




1.04min) in the transversal plane was made before and 7 times after intravenous 
administration of 0.1 mmol/kg DOTAREM (0.5mmol Gd/ml). The total duration of the 
dynamic study was approximately 9 minutes.  
 
Multivoxel MR spectroscopy 
The breast lesion was localized on DWI and T2 weighted images. After the location of the 
breast lesion was determined the transverse and sagittal T2-weighted fast spin-echo series 
covering both breasts (TR/TE 4500/102ms) performed without distortion correction were 
used for MR spectroscopy planning. The spectroscopic imaging protocol [38] included 2D-
CSI with point resolved spectroscopy (PRESS) double spin-echo with phase-encoding 
gradients between the slice selective 900 pulse and the first slice-selective optimized 1800 
pulse. 2D-CSI of the breast was performed twice, first without suppression of the water and 
fat signals (TR/TE 1500/30ms) to serve as a reference measurement. The second 
measurement was with suppression of the water and fat signals (TR/TE 1500/135ms) 
(acquisition time 4:46 min). The field of view was 8x8 cm to roughly cover the transverse 
cross section of the examined breast, subdivided into 144 phase encode steps to yield voxels of 
0.67x0.67x1 cm at the used slice thickness of 1 cm. In this hybrid CSI technique the volume of 
interest was smaller than the field of view (3x3x1 cm) in order to end up with essentially 
measuring the watery part of the breast (glandular breast tissue, pathology). Unwanted water 
and lipid signals were suppressed by band selective inversion with gradient dephasing 
(BASING) [38]. 
The multivoxel MR spectroscopy was performed before the T1-weighted images with 
contrast administration to prevent possible interference of metal chelate with the 





Subtracted images were obtained by subtracting pre-contrast images from the post-contrast 
images using commercially available software. MRI scans were coded using the ordered 





no enhancement was seen in the expected location of the mammographic finding (BI-
RADS 1) or only homogeneous or stippled enhancement was found in the breast, 
representing normal enhancing breast parenchyma or fibrocystic changes (BI-RADS 2). 
The lesions which were detected on the MRI and corresponded with the area to the 
mammographic finding were classified as focus, mass enhancement or non-mass 
enhancement. From the enhancing lesions the location, lesion type, shape, border, 
distribution, internal enhancement and kinetic curves according to the BI-RADS lexicon 
were assessed and the lesions were classified as BI-RADS 3, 4 or 5 [7]. 
 
Multivoxel MR spectroscopy 
In the post-processing 12x12 phase encode steps were interpolated into a 16x16 matrix, i.e. 
voxels appearing as 0.5x0.5x1 cm3. The number of MR spectroscopic peaks fitted included 
the chemical shift ranges restricted to 3.1-3.3 ppm for Cho, 4.5-5.0 ppm for water, and 1.0-
1.5 ppm for the main resonance of fat (-CH2-). Standardized postprocessing protocols were 
used for processing the raw data automatically, allowing for operator-independent 
quantifications. 
For each lesion the highest concentration of the metabolite Cho amongst the various 
corresponding voxels was calculated from the relative peak areas of the resonances of Cho 
(N(CH3)3 at 3.23 ppm), denoted SM, and water (H2O at 4.7 ppm) using the following 
formula: 
 
[SM] = SM/SH2O x TWC x 1/MwH2O x nH2O/nM x T1satH2O/T1satM x T2satH2O/T2satM  
 
To express concentrations in molar units (mol/L of tissue volume), literature values were 
adapted for the tissue water contents (TWC) of voxels containing breast tumour tissue, 82% 
[28]: nH2O is 2, and nCho is 9. MwH2O stands for the molecule weight of water. 
The T1 saturation factors and T2 saturation factors for water, Cr and Cho were calculated 
using literature values for T1 and T2 relaxation times of water and Cho as described 
elsewhere [38]. 





Breast lesions which MRI classified as BI-RADS 2 were considered benign and BI-RADS 
3, 4 and 5 lesions were considered positive for malignancy.  Sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) of breast contrast-enhanced 
MRI were calculated on the basis of final pathology reports. 
The mean and standard deviation of the highest Cho concentration of, respectively, all 
benign and malignant lesions were calculated. Differences between the Cho measurements 
of benign and malignant breast lesions were tested for significance using the independent 
sample T test. A P-value < .05 was considered as statistically significant. Receiver 
operating characteristics (ROC) analysis was used to quantify the diagnostic accuracy of 
contrast-enhanced MRI and multivoxel MR spectroscopy in the assessment of breast 
lesions. Data were analyzed in SPSS 16.0 (SPSS inc 2009, Chicago) and STATA SE 




The indication for undergoing mammographic examination was a palpable breast lesion in 
17 (68.0%) patients. In 3 (12.0%) patients a suspicious lesion was found during the 
National Dutch Breast Cancer Screenings Programme. Three (12.0%) patients were 
screened because of high risk for breast cancer. Two (8.0%) patients had a mammography 
because of an enlarged lymph node in the axilla. 
 
Breast lesions 
Twenty-six breast lesions were assessed (1 patient had both a mammographic BI-RADS 3 
lesion and a BI-RADS 4 lesion in the same breast). Ten (38.5%) out of 26 breast lesions 
were classified as BI-RADS 3 and 16 (61.5%) breast lesions as BI-RADS 4 on the 
mammogram. The size of the benign lesions as seen on MRI varied between 10 and 21 mm. 





Table 1 MRI BI-RADS classification, number of voxels and the mean and standard deviation (SD) of 
the highest Cho concentration in benign and malignant breast lesions. 
 
MRI BI-RADS Classification Number of  Highest Cho concentration (mM)  
(number of benign+malignant lesions) voxels (range) (mean±SD) 
      _________________________________________ 
  Total Benign Malignant P-value 
 
 
5 BI-RADS 2 lesions (5+0) 2-6 1.16±0.43 1.16±0.43  
8 BI-RADS 3 lesions (6+2) 2-6 1.43±0.47 1.22±0.26 2.05±0.35 .01 
5 BI-RADS 4 lesions (0+5) 2-7 2.98±2.15  2.98±2.15 
8 BI-RADS 5 lesions (0+8) 3-14 4.94±3.10  4.94±3.10  
 




MRI BI-RADS classification and multivoxel MR spectroscopy 
MRI classified the 26 breast lesions as BI-RADS 2 (n=5; 19.2%), as BI-RADS 3 (n=8; 
30.8%), as BI-RADS 4 (n=5; 19.2%) and as BI-RADS 5 (n=8; 30.8%). The means of the 
highest Cho concentrations detected in these BI-RADS categories were 1.16±0.43SD for 
five BI-RADS 2 lesions, 1.43±0.47SD for eight BI-RADS 3 lesions, 2.98±2.15SD for five 




a b c 
Fig. 1 Volume of interest (36 voxels of 0.25 cm3 each) centered on an invasive lobular carcinoma in 
the right breast of a 67-year- old patient and spectral map showing intense water and minor fat peaks 
in the lesion (a). After application of water and fat suppression intense Cho signals are detected in the 
whole lesion as shown in green on the metabolic map (b). The highest detected Cho level (the red 
voxel in the metabolic map) is used for quantification. The sum of all tumor MR spectra together is 
shown  in (c). 




The five BI-RADS 2 lesions with a mean Cho concentration of 1.16mM were benign: 3 
fibroadenomas and 2 showed no malignant cells after FNAB.  
Two out of eight BI-RADS 3 lesions turned out to be malignant and showed a mean Cho 
concentration of 2.05mM. These 2 breast lesions were an invasive ductal carcinoma and an 
invasive lobulair carcinoma. The other six MRI BI-RADS 3 lesions were benign and had a 
mean Cho concentration of 1.22mM. One out of 6 benign breast lesions showed no 
malignant cells in the FNAB and the histology of the other five lesions were: 2 
fibroadenomas, lobular hyperplasia without atypia, epithelial hyperplasia without atypia 
and fibrosis with apocrine metaplasia. There was a significant difference in Cho 
concentration between the benign and malignant breast lesions in BI-RADS 3 category 
(P=.01). 
All five MRI BI-RADS 4 lesions and all eight MRI BI-RADS 5 lesions with a mean Cho 
concentration of 2.98mM and 4.94mM, respectively, showed malignancy after surgery: 10 





Fig. 2 ROC curves for the comparison of breast MRI and multivoxel MR spectroscopy in the 





There was a significant difference between all benign and malignant lesions for the Cho 
concentration (P = .01). Furthermore, there was no overlap between the ranges in benign 
(0.4-1.5mM (1.19±0.33SD)) and malignant lesions (1.7-11.8mM (4.03±2.72SD)) (Table 1, 
2). 
Breast MRI without multivoxel MR spectroscopy had a sensitivity of 100%, specificity of 
45.5%, PPV of 71.4% and NPV of 100%. ROC analysis revealed an area under the curve 
(AUC) of 0.96±0.03 (95% CI: 0.91-1.00) for the accuracy of breast MRI in the assessment 
of breast lesions. Using a threshold of the Cho concentration of 1.5mM as the distinction 
between benign en malignant lesions, the ROC analysis for multivoxel MR spectroscopy 
revealed an AUC of 1.00 (95% CI: 1.00-1.00) (Fig. 2). 
 
 
Table 2 Mammographic and MRI BI-RADS classification, number of voxels, the highest Cho 
concentration and pathology for 26 breast lesions. 
 
Mammographic MRI BI-RADS No. of  Highest Cho Pathology  
BI-RADS categroy category voxels conc (mmol/l) 
 
10 BI-RADS 3 4 BI-RADS 2 6 0.4 Fibroadenoma 
  2 1.3 Fibroadenoma 
  2 1.3 No malignant cells 
  4 1.5 No malignant cells 
 5 BI-RADS 3 6 1.3 Fibroadenoma 
  2 1.3 Fibroadenoma 
  4 1.5 Fibrosis with apocrine metaplasie 
  4 1.0 Lobular hyperplasia without atypia 
  4 0.8 No malignant cells 
 1 BI-RADS 4 4 2.4 Invasive ductal carcinoma 
 
16 BI-RADS 4 1 BI-RADS 2 2 1.3 Fibroadenoma 
 3 BI-RADS 3 5 1.4 Epithelial hyperplasia without atypia 
  2 1.8 Invasive ductal carcinoma  
  2 2.3 Invasive lobular carcinoma 
 4 BI-RADS 4 2 1.7 Invasive ductal carcinoma 
  2 1.8 Invasive ductal carcinoma 
  3 2.2 Invasive ductal carcinoma 
  7 6.8 Invasive ductal carcinoma 
 8 BI-RADS 5 3 2.5 Invasive ductal carcinoma 
  4 4.1 Invasive ductal carcinoma 
  4 2.4 Invasive ductal carcinoma 
  6 4.6 Invasive ductal carcinoma 
  4 6.8 Invasive ductal carcinoma 
  5 11.8 Invasive lobular carcinoma 
  14 3.4 Invasive lobular carcinoma (Fig. 1) 
  7 3.9 Metaplastic carcinoma 
 






Breast MRI is an important diagnostic modality and with a NPV of 97% [4-6] it can safely 
exclude malignancy. Also in this study the NPV of breast MRI is very high (100%) and 
therefore no further invasive diagnostic work-up is needed when breast lesions are assessed 
as BI-RADS 2 with MRI. However, breast MRI is still not perfect. Today BI-RADS is the 
communication tool in breast MRI reports and the most difficult breast lesions are the 
lesions which are classified as BI-RADS 3 with MRI. The probability of a mammographic 
BI-RADS 3 lesion being cancer is considered to be less than 2 % by AHQR [11], but the 
acceptable cancer yield is not clearly defined for MRI BI-RADS 3 lesions. There are 5 
articles that included data in the MRI BI-RADS 3 assessment category, with a resulting 
wide range of cancer yields (0.6-10%) [4,43-46]. Although, the diagnostic work-up of a BI-
RADS 3 lesion can be a biopsy (instead of a follow-up breast MRI after six months) over 
90% of patients who are referred for biopsy have a benign disease. 
This present study indicates that non-invasive quantitative multivoxel MR spectroscopic 
technique can be an additional tool for contrast-enhanced MRI in the assessment of breast 
lesions. The accuracy of breast MRI is excellent, but according to our preliminary results 
multivoxel MR spectroscopy show an AUC of 1.00. There was no overlap between the 
outcomes of benign and malignant lesions for the highest Cho concentration, 0.4-1.5 mM 
and 1.7-11.8 mM, respectively. Cho concentrations over 1.5 mM are not found in benign 
lesions, such as fibroadenomas. In our study benign breast lesions which were classified as 
BI-RADS 3 with MRI had a highest Cho concentration ≤ 1.5mM and were significantly 
different (P = .01) from malignant BI-RADS 3 lesions. In this way patients with benign BI-
RADS 3 lesion can be excluded from further invasive diagnostic work-up. Accordingly, it 
can be expected that the added value of noninvasive multivoxel MR spectroscopy applies to 
the MRI classified BI-RADS 3 lesions. 
There are only 3 previous studies featuring the diagnostic value of combined contrast-
enhanced MRI and multivoxel MR spectroscopy in evaluating breast lesions. The 
conclusion of these 3 studies is that multivoxel MR spectroscopy appears to be a promising 
technique for classification of breast lesions when contrast-enhanced MRI results are 





tool is to reach a high sensitivity at the cost of  the specificity, the metabolic information 
measured by multivoxel MR spectroscopy may be used to improve the specificity in the 
diagnosis of breast tumors [34,36,37]. In the study of Beak et al. [34] multivoxel MR 
spectroscopy had a sensitivity of 81%, specificity of 78% and overall accuracy of 81% with 
the use of ROC analysis. These outcomes show a lower sensitivity and specificity then the 
results in our study. A limitation of the 3 studies is that the area of the Cho was measured in 
the lesion and expressed relative to the background noise level (signal-to-noise ratio), 
which is no quantitative measurement of Cho [34,36,37]. In our quantitative multivoxel MR 
spectroscopic study the detectability of abnormalities in Cho level is improved by the 
measurement of the highest lesion Cho concentration with the ability to analyze the 
regional distribution of tumor metabolites.  
A limitation of our study is that a small patient population is included. Despite this, it is 
clear that in these breast lesions there is no overlap between the Cho concentration of 
benign and malignant breast lesions. Another limitation is that only breast lesions ≥ 1cm3 
were included, reflecting the limited sensitivity of MR spectroscopy (voxels sixes were 
0.25 cm3). Smaller breast lesions will have the problem that the measured lesion Cho levels 
are reduced by partial volume effects, reducing the changes of being able to demonstrate a 
malignant Cho profile. In the future the use of more sensitive MRI scanners operating at 3T 
and up may be expected to allow for the inclusion of smaller lesions. Also, in this study the 
breast lesions were assessed on DWI and T2-weighted imaging for the MR spectroscopy 
planning and not on the contrast-enhanced T1-weighted images to avoid the likely 
influence of contrast medium on the measured Cho concentration. This can be a problem if 
the breast lesion is not visible with the first two sequences (DWI and T2). Furthermore, the 
methodology of this study has some technical limitations regarding to partial volume 
effects, water and fat suppression, whole breast coverage in acceptable scan times and 
quantification. Nevertheless, in this quantitative multivoxel MR spectroscopic study Cho 
concentrations are measured more accurately and a significant difference (P=.01) between 
benign and malignant lesions for the highest Cho concentration is shown.  
In conclusion, this study indicates that the noninvasive quantitative multivoxel MR 
spectroscopic technique can improve the accuracy of contrast-enhanced MRI in the 
assessment of breast lesions, especially for breast lesions classified as BI-RADS 3. A Cho 




concentration over 1.5 mM is not found in benign breast lesions with a volume ≥1cm3 and 
therefore these lesions can be excluded from further diagnostic work-up. Nevertheless, 
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Worldwide incidence of breast cancer is higher than incidence of other malignancies among 
women. In the Netherlands approximately one out of eight women will develop breast 
cancer during life. Although the incidence has increased, mortality has decreased during the 
last two decades and at the moment the risk of dying of breast cancer is 1 of 26. This 
reduction in mortality is partly due to early detection of malignancies in screening and 
partly due to more and better adjuvant therapies. 
In chapter 1 of this thesis a general introduction is given concerning mammography, breast 
Magnetic Resonance Imaging (MRI), Computer Aided Detection (CAD) systems and MR 
spectroscopy (MRS). 
Mammography is the primary imaging modality for the early detection of breast cancer. 
Despite advances in mammographic techniques (digital), mammography still has its 
limitations with regard to both sensitivity (39%-86%) and specificity (88%-94%), which 
depends on age and breast density.  Mammograms and breast Magnetic Resonance Imaging 
(MRI) are coded using the ordered categories of the Amercian College of Radiology (ACR)  
Breast Imaging Reporting and Data System (BI-RADS) lexicon: category 1, negative 
(normal finding); category 2, benign finding; category 3, probably benign; category 4, 
suspicious finding; category 5, highly suggestive of malignancy and category 6, 
pathologically proven breast cancer. The diagnostic work-up of breast lesions depends on 
the BI-RADS classification of these lesions. The most difficult mammographic lesions are 
the lesions which are classified as BI-RADS 3 of which it is not possible to decide whether 
they are malignant or benign. The probability of a BI-RADS 3 lesion to be malignant is 
considered to be less than 2%. In recent publications, this percentage seems to have been 
increased up to approximately 15% in the last 5 years. The diagnostic work-up of a BI-
RADS 3 lesion can be a biopsy or follow-up mammography after six months. Because of 
the limited accuracy of both physical examination and mammography, a large majority of 
patients referred for biopsy has a benign lesion. Breast MRI is emerging as a clinically 
useful additional diagnostic tool, but there are sparse data available to support the use of 
breast MRI as problem solving modality in mammographic BI-RADS 3 lesions and, 





highest overall sensitivity, which usually exceeds 90%, of all imaging techniques. In non-
calcified lesions a negative breast MRI shows a sufficient high negative predictive value 
(NPV>98%) to safely exclude malignancy. Thus, in chapter 2 the usefulness of breast MRI 
as a problem solving modality in patients with mammographic BI-RADS 3 lesions is 
investigated in a meta-analysis. Five out of 61 studies met the inclusion criteria. In two out 
of these 5 studies the role of breast MRI in non-calcified mammographic BI-RADS 3 
lesions was investigated. These 2 studies reported a NPV of 100%. In the other 3 studies, 
mammographic BI-RADS 3 microcalcifications were included. The NPV of MRI was 
between 76%-97%. Therefore, breast MRI cannot be implemented as a primary diagnostic 
tool to evaluate mammographic microcalcifications at this time. Although solid data are 
sparse, the first ones indicate that breast MRI might be useful as problem solving modality 
to exclude patients with non-calcified mammographic BI-RADS 3 lesions for further 
diagnostic work-up. 
Therefore, in chapter 3, 76 patients with a mammographic BI-RADS 3 lesion underwent 
breast MRI as diagnostic work-up. The purpose of the study was to investigate whether 
breast MRI can provide a sufficient NPV to safely rule out malignancy and decrease the 
percentages of invasive diagnostic procedures in mammographic BI-RADS 3 lesions. 
Lesions classified as BI-RADS 1 or 2 with MRI were considered negative for malignancy. 
This was the case for 52 (68.4%) out of 76 patients and no malignancies were found during 
at least 2 years study follow-up. MRI had a sensitivity of 100% (95% CI: 75-100%), 
specificity of 82.5% (95% CI: 71-91%), positive predictive value of 54.2% (95% CI: 33-
74%) and NPV of 100% (95% CI: 93-100%). In conclusion, breast MRI should be used in a 
diagnostic strategy for the work-up of non-calcified BI-RADS 3 lesions, because the NPV 
of MRI is high enough (>98%) to rule out malignancy with sufficient confidence. In the 
majority of patients (68%) no further invasive diagnostic assessment is needed, when the 
MRI is assessed as BI-RADS 1 or 2. 
The postprocessing and interpretation of breast MRI data is time consuming and operator 
dependent. Computer Aided Detection (CAD) programs for MR imaging of breast lesions 






CAD systems help the radiologist to determine which lesions are benign and which are 
malignant by automating extraction and interpretation of kinetic curves (the enhancement 
pattern of lesions). A state of the art CAD system should automatically identify (almost) all 
non-calcified lesions suspected of malignancy at mammography. This is reflected by a very 
high sensitivity and NPV for these non-calcified breast lesions. In a systematic review and 
meta-analysis (chapter 4) the additional value of a CAD system in breast MRI is 
investigated by assessing radiologists’ accuracy in discriminating benign from malignant 
breast lesions with and without CAD implementation. Experienced radiologists reached 
comparable pooled sensitivity and specificity before and after using CAD (sensitivity: 
without CAD: 89%; 95% CI: 78-94%, with CAD: 89%; 95%CI: 81-94%) (specificity: 
without CAD: 86%; 95% CI: 79-91%, with CAD: 82%; 95% CI: 76-87%). For residents 
the pooled sensitivity increased from 72% (95% CI: 62-81%) without CAD to 89% (95% 
CI: 80-94%) with CAD, however, not significantly. Concerning specificity, the results were 
similar (without CAD: 79%; 95% CI: 69-86%, with CAD: 78%; 95% CI: 69-84%). In 
conclusion, the assessment of MR images with CAD has little influence on the sensitivity 
and specificity of the performance of radiologists experienced in breast MRI diagnosis. 
Therefore, breast MRI interpretation by radiologists remains essential. Residents or 
radiologists with less experience seem to benefit from a CAD system when performing 
breast MRI evaluation. 
Breast MRI seems to have a sufficiently high NPV for non-calcified breast lesions, when 
the criteria for these lesions, which are partly based on kinetic and morphological analysis, 
are applied strictly. The remaining breast lesions (approximately 30%) show considerable 
overlap in enhancement between benign and malignant breast lesions. Therefore, in some 
cases (mostly BI-RADS 3 lesions), enhancement patterns may be equivocal and additional 
diagnostic methods may be needed for clarifications. In addition to morphological and 
kinetical analysis, metabolic information is expected to be promising for the final diagnosis 
of breast lesions. In vivo proton (1H) MR spectroscopy of the breast provides metabolic 
information about the investigated tissue in a non-invasive manner. MR spectroscopy can 
be performed as single-voxel or multivoxel technique. The diagnostic value of MR 
spectroscopy is generally based on the detection of elevated levels of choline (Cho) 





breast tumor. Namely, in recent studies Cho signals were also detected in benign lesions 
and normal breast tissues. Therefore, the presence of a Cho-related peak in breast MR 
spectroscopy is not sufficient for a non-invasive diagnosis of malignancy. Quantification of 
the Cho compounds peak is required to determine the accurate levels of Cho. Multivoxel 
MR spectroscopic studies, while potentially allowing for truly quantitative tissue 
characterization, have up to now also been far from quantitative with the use of the Cho 
signal-to-noise ratio as measure of tumor activity. Therefore, in chapter 5 a quantitative 
multivoxel MR spectroscopy method for the examination of pathology in the human breast 
is presented. The concentration of Cho can be determined in different tumor compartments 
and surrounding tissues in two brief multivoxel MR spectroscopic measurements, even 
when using a daily routine 1.5T MRI system. In chapter 6 the optimal cutoff of Cho 
concentration in quantitative multivoxel MR spectroscopic data to exclude benign lesions 
from further invasive diagnostic work-up is determined. Multivoxel MR spectroscopy was 
performed in 24 consecutive patients with 25 breast lesions assessed as BI-RADS 3 or 4, 
and larger than 1 cm diameter at mammography. Mean and highest Cho concentrations in 
benign and malignant breast lesions differed significantly (P =.02, both). The results of this 
study, in a relatively small patient population, show that quantitative multivoxel MR 
spectroscopy can be applied to exclude benign breast lesions with a volume ≥1 cm3 from 
further invasive diagnostic work-up with the implementation of a Cho concentration ≤ 1.5 
mM as cutoff. Whether the Cho level measured by quantitative multivoxel MR 
spectroscopy can increase the accuracy of contrast-enhanced MRI in the assessment of 
breast lesions is investigated in chapter 7. Twenty-five consecutive patients with 26 breast 
lesions ≥1 cm assessed as BI-RADS 3 or 4 with mammography underwent quantitative 
multivoxel MR spectroscopy and contrast-enhanced breast MRI. The Cho concentration of 
15 malignant breast lesions was significantly higher (P = .01) than the Cho concentration in 
the 11 benign lesions. Furthermore, Cho concentrations between the benign and malignant 
lesions which were classified as BI-RADS 3 by MRI differed (P = .01). This study 
indicates that the accuracy of multivoxel MR spectroscopy added to the breast MRI BI-






The focus of this PhD thesis is to prevent unnecessary invasive procedures in breast cancer 
diagnostic work-up for women with a probably benign (BI-RADS 3) breast lesion. For 
mammographic non-calcified BI-RADS 3 lesions breast MRI can provide a sufficiently 
high NPV (>98%) for early diagnostic work-up and thereby safely rule out malignancy in a 
majority of patients (68%), herewith avoiding unnecessary invasive diagnostic procedures. 
The use of a state of the art CAD system should automatically identify (almost) all non-
calcified lesions suspected of malignancy, but the implementation of a CAD system for 
these breast MRIs’ evaluation has little influence on the accuracy of the performance of an 
experienced radiologist. However, short time (10 minutes), non-invasive quantitative 
multivoxel MR spectroscopy on a 1.5T system can increase the accuracy of breast MRI. A 
Cho concentration >1.5mM is not found in benign breast lesions with a volume ≥1cm3 and 
therefore these lesions can be excluded from further unnecessary invasive diagnostic 
procedures. Nevertheless, larger patient samples are needed to strengthen this conclusion 













De wereldwijde incidentie van borstkanker is hoger dan de incidentie van andere vormen 
van kanker onder vrouwen. In Nederland krijgt ongeveer 1 op de 8 vrouwen borstkanker. 
Hoewel de incidentie is gestegen, is de mortaliteit de laatste twee decennia afgenomen en 
op dit moment is het risico op overlijden aan borstkanker 1 op 26. Deze afname in 
mortaliteit komt gedeeltelijk door het vroegtijdig opsporen van borstkanker door screening 
en gedeeltelijk door meer en betere aanvullende behandelingen. 
In hoofdstuk 1 van dit proefschrift wordt een algemene introductie gegeven over 
mammografie, mamma Magnetic Resonance Imaging (MRI), Computer Aided Detection 
(CAD) systemen en MR spectroscopie (MRS).  
Mammografie is de eerste keus voor het vroegtijdig opsporen van borstkanker. Ondanks de 
voordelen van mammografie (digitaal), heeft mammografie nog steeds beperkingen met 
betrekking tot de sensitiviteit (39%-86%) en specificiteit (88%-94%), die afhankelijk zijn 
van de leeftijd van de vrouw en de dichtheid van het borstweefsel. Mammogrammen en 
mamma MRI’s worden gecodeerd aan de hand van de categorieën van de “Amercian 
College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS)” 
lexicon: categorie 1, negatief (normale bevindingen); categorie 2, benigne laesie 
(=goedaardige afwijking); categorie 3, waarschijnlijk benigne; categorie 4, waarschijnlijk 
maligne (=kwaadaardig); categorie 5, zeer verdacht voor maligniteit; categorie 6, 
pathologisch bewezen voor borstkanker. De keuze voor diagnostisch onderzoek van 
mamma-afwijkingen is afhankelijk van welke BI-RADS categorie is gegeven aan de  
afwijking. Over de afwijkingen die op het mammogram als BI-RADS 3 geclassificeerd zijn 
is het niet mogelijk een uitspraak te doen in termen van maligniteit of benigniteit. De kans 
dat een BI-RADS 3 afwijking maligne is, was voorheen kleiner dan 2% en is tot op heden 
het uitgangspunt. Dit percentage neemt echter de laatste 5 jaar toe tot circa 15%, gelet op de 
meer recente publicaties. Het vervolg-diagnostisch onderzoek bij BI-RADS 3 afwijkingen 
bestaat uit een biopsie procedure of een follow-up na 6 maanden. Vanwege het feit dat het 
klinisch borstonderzoek en mammografie een beperkte diagnostische accuraatheid hebben, 
blijkt het merendeel van de patiënten, die een biopsie procedure ondergaan, een benigne 





onderzoek, maar er is maar een beperkt aantal studies gedaan die het gebruik van een 
mamma MRI als probleemoplossend diagnostisch onderzoek bij mammografische BI-
RADS 3 afwijkingen ondersteunt. Daarom wordt een mamma MRI niet gebruikt in de 
dagelijkse praktijk. Echter, mamma MRI heeft, in zijn algemeenheid, de hoogste 
sensitiviteit van alle beeldvormende technieken, die in de meeste studies de 90% 
overschrijdt. In niet-gecalcificeerde mamma-afwijkingen heeft een negatieve mamma MRI 
een zeer hoog negatief voorspellende waarde (NVW>98%) waardoor een maligniteit met 
een zeer hoge betrouwbaarheid kan worden uitgesloten. Vandaar dat in hoofdstuk 2 het 
gebruik van een mamma MRI als probleemoplossend diagnostisch onderzoek in patiënten 
met een BI-RADS 3 afwijking wordt onderzocht in een meta-analyse. Vijf van de 61 
studies voldeden aan de inclusiecriteria. In 2 van deze 5 studies werd de rol van MRI in 
mammografische niet-gecalcificeerde BI-RADS 3 afwijkingen onderzocht. Deze 2 studies 
rapporteerde een NVW van 100%. In de ander 3 studies werden mammografisch BI-RADS 
3 microcalcificaties geїncludeerd. De NVW van de MRI bij deze ongeselecteerde 
patiëntengroep was tussen de 76%-97%. MRI dient dan ook niet te worden toegepast als 
primair diagnosticum bij de aanwezigheid van microcalcificaties. Ondanks het feit dat er 
weinig studies zijn, tonen de eerste goed opgezette studies aan dat mamma MRI bruikbaar 
kan zijn als probleemoplossend diagnostisch onderzoek bij patiënten met niet-
gecalcificeerde BI-RADS 3 afwijkingen. Om dit in de praktijk vast te stellen ondergingen 
in de studie in hoofdstuk 3 76 patiënten met een mammografische BI-RADS 3 afwijking 
een mamma MRI als diagnostisch onderzoek. Het doel van deze studie is om te 
onderzoeken of de NVW van mamma MRI zo hoog is dat een maligniteit betrouwbaar kan 
worden uitgesloten bij klinische implementatie, met als gevolg dat het percentage invasieve 
diagnostische procedures in mammografische BI-RADS 3 afwijkingen substantieel wordt 
verminderd. Afwijkingen die geclassificeerd werden als BI-RADS 1 of 2 op de MRI 
werden beschouwd als negatief voor maligniteit. Dit was het geval voor 52 (68.4%) van de 
76 patiënten, waarbij geen maligniteit werd gevonden gedurende tenminste 2 jaar studie 
follow-up. MRI had een sensitiviteit van 100% (95% CI: 75-100%), specificiteit van 82.5% 
(95% CI: 71-91%), positief voorspellende waarde (PVW) van 54.2% (95% CI: 33-74%) en 
NVW van 100% (95% CI: 93-100%). Conclusie is dat mamma MRI gebruikt kan worden 





NVW van MRI zo hoog is (>98%) dat maligniteit betrouwbaar kan worden uitgesloten 
voor de klinische praktijk. In de meerderheid van de patiënten (68%), wanneer de afwijking 
op de MRI wordt beoordeeld als BI-RADS 1 of 2, is geen verdere invasief diagnostisch 
onderzoek nodig. 
De postprocessing en het beoordelen van een mamma MRI kost tijd en is afhankelijk van 
de radioloog. Er zijn Computer Aided Dectection (CAD) programma’s ontwikkeld voor het 
standaardiseren en het vergemakkelijken van het beoordelen van MRI beelden met 
mamma-afwijkingen. Een CAD systeem helpt de radioloog om een mamma MRI te 
beoordelen door automatische extractie van beelden en de interpretatie van kinetische 
curven (het aankleuringspatroon van de afwijkingen). Een “state of the art” CAD syteem 
zal automatisch alle niet-gecalcificeerde afwijkingen verdacht voor maligniteit op 
mammografie moeten herkennen. Dit vanwege de hoge sensitiviteit en NVW van niet-
gecalcificeerde mamma-afwijkingen. In een systematische review en meta-analyse 
(hoofdstuk 4) wordt de aanvullende waarde van een CAD systeem in mamma MRI 
onderzocht door te beoordelen hoe nauwkeurig de radioloog is in het onderscheiden van 
benigne en maligne mamma- afwijkingen met en zonder een CAD systeem. Ervaren 
radiologen hadden een vergelijkbare gepoolde sensitiviteit en specificiteit voor en na het 
gebruik van een CAD systeem (sensitiviteit: zonder CAD: 89%; 95% CI: 78-94%, met 
CAD: 89%; 95%CI: 81-94%) (specificiteit: zonder CAD: 86%; 95% CI: 79-91%, met 
CAD: 82%; 95% CI: 76-87%). Voor arts-assistenten steeg de gepoolde sensitiviteit van 
72% (95% CI: 62-81%) zonder CAD naar 89% (95% CI: 80-94%) met CAD, maar dit was 
niet significant. De resultaten van de specificiteit waren gelijk (zonder CAD: 79%; 95% CI: 
69-86%, met CAD: 78%; 95% CI: 69-84%). Geconcludeerd is dat een CAD systeem 
weinig invloed heeft op de sensitiviteit en specificiteit van de ervaren radioloog in het 
beoordelen van mamma MRI beelden. Daarom blijft de visuele interpretatie van de 
radioloog van essentieel belang. Arts-assistenten of onervaren radiologen hebben wel baat 
bij het gebruik van een CAD systeem bij het evalueren van een mamma MRI. 
Bij strikte toepassing van de criteria voor een negatieve afwijking die ten dele ook op grond 
van kinetische en morfologische gegevens gemaakt wordt, blijkt dat een mamma MRI een 
zeer hoge NVW heeft voor niet-gecalcificeerde mamma afwijkingen. De overige 





maligne afwijkingen. Daarom zal er in een aantal gevallen (vooral bij BI-RADS 3 
afwijkingen) geen duidelijkheid over de afwijking zijn en is een aanvullend diagnostisch 
onderzoek nodig. Als aanvulling op de morfologische en kinetische analyse wordt verwacht 
dat metabole  informatie veelbelovend is voor de einddiagnose van een mamma-afwijking. 
Met in vivo proton (1H) MR spectroscopie van de mamma wordt op een niet-invasieve 
methode metabole informatie verkregen van het mammaweefsel. MR spectroscopie kan als 
single-voxel of als multivoxel techniek worden uitgevoerd. De diagnostische waarde van 
MR spectroscopie is gebaseerd op het detecteren van verhoogde choline bevattende 
componenten (Cho), die tot op zekere hoogte als een marker van een actieve maligne 
mamma afwijking kunnen dienen. In recente studies werden namelijk ook Cho signalen 
gevonden in benigne mamma afwijkingen en gezond klierweefsel. Dit is de reden dat de 
aanwezigheid van een Cho piek in mamma MR spectroscopie niet toereikend is voor een 
niet-invasieve diagnose van een maligne afwijking. Kwantificatie van de Cho piek is vereist 
om nauwkeurig de hoogte van de Cho concentratie te bepalen. Multivoxel MR 
spectroscopie studies hebben de potentie om Cho in het mammaweefsel te kwantificeren, 
maar in de tot nu toe gepubliceerde studies wordt op een niet-kwantitatieve manier, 
namelijk de Cho signaal-ruis verhouding gemeten voor de tumor activiteit. Daarom wordt 
in hoofdstuk 5 een kwantitatieve multivoxel MR spectroscopie methode voor het 
beoordelen van pathologie in de mamma gepresenteerd. De concentratie van Cho kan 
bepaald worden in verschillende tumor compartimenten en het omliggende weefsel in 2 
korte multivoxel MR spectroscopiemetingen, zelfs bij het gebruik van een 1.5T MRI 
systeem. In hoofdstuk 6 wordt het optimale afkappunt van Cho concentratie in 
kwantitatieve multivoxel MR spectroscopiedata bepaald om benigne afwijkingen uit te 
sluiten voor verder invasief diagnostisch onderzoek. Multivoxel MR spectroscopie werd 
toegepast bij 24 vrouwen met 25 mamma-afwijkingen ≥ 1 cm en geclassificeerd als BI-
RADS 3 of 4 op het mammogram. De gemiddelde en hoogste Cho concentraties in benigne 
en maligne mamma- afwijkingen verschilden significant van elkaar (P = .02). Deze studie, 
in een kleine studiepopulatie, laat zien dat kwantitatieve multivoxel MR spectroscopie 
gebruikt kan worden om patiënten met benigne afwijkingen ≥ 1cm uit te sluiten van verder 





Of de gemeten Cho concentratie van mamma afwijkingen met kwantitatieve multivoxel 
MR spectroscopie methode de nauwkeurigheid kan verhogen van een mamma MRI 
beoordeling wordt onderzocht in hoofdstuk 7. 25 Patiënten met 26 mamma afwijkingen ≥1 
cm en beoordeeld als BI-RADS 3 of 4 op het mammogram ondergingen kwantitatieve 
multivoxel MR spectroscopie en mamma MRI. De Cho concentratie van 15 maligne 
mamma-afwijkingen  was significant (P = .01) hoger dan de Cho concentratie in 11 
benigne afwijkingen. Verder verschilde de Cho concentratie tussen de benigne en maligne 
afwijkingen die door de MRI geclassificeerd waren als BI-RADS 3 significant (P = .01). 
Uit deze studie blijkt dat de nauwkeurigheid van multivoxel MR spectroscopie toegevoegd 
aan de mamma MRI BI-RADS classificatie (AUC=1.00) in vergelijking met de 
nauwkeurigheid van mamma MRI alleen (AUC=0.96±0.03) overschrijdt.  
 
Conclusie 
De essentie van dit proefschrift is vrouwen met een waarschijnlijk benigne afwijking (BI-
RADS 3) onnodige invasieve procedures in diagnostisch borstkanker work-up te besparen. 
Voor niet-gecalcificeerde mammografische BI-RADS 3 afwijkingen blijkt mamma MRI 
een zo hoge NVW (>98%) te hebben, dat een maligniteit betrouwbaar kan worden 
uitgesloten in de meerderheid (68%) van de patiënten met deze classificatie. Hierdoor 
kunnen onnodige invasieve diagnostische onderzoeken worden voorkomen. Gebruik van 
een “state of the art” CAD systeem dat is ontworpen om automatisch alle niet-
gecalcificeerde afwijkingen verdacht voor maligniteit te herkennen, blijkt bij een ervaren 
radioloog weinig toe te voegen aan zijn visuele beoordeling van deze mamma MRI’s. Wel 
kan een kortdurend (10 minuten), niet-invasief kwantitatief multivoxel MR-
spectroscopieonderzoek op een 1.5T MRI-systeem de nauwkeurigheid van mamma MRI 
verhogen. In benigne mamma-afwijkingen met een volume ≥1cm3 werden geen choline 
concentraties >1.5mM gevonden, waardoor deze afwijkingen uitgesloten kunnen worden 
van verdere onnodige invasieve diagnostisch procedures. Echter, meer onderzoek in een 
nog grotere patiëntengroep is nodig om uitspraken te kunnen doen over de implementatie 













In 2007 begonnen als arts-onderzoeker verbonden aan de NELSON studie, maar na een jaar 
erachter gekomen dat mijn passie ligt bij mammaonderzoek. Uit het niks werd een mooi 
onderzoek opgebouwd met als resultaat dit proefschrift. Dit was niet mogelijk geweest 
zonder de hulp van velen. Daarom wil ik iedereen bedanken die een bijdrage heeft geleverd 
aan de totstandkoming van dit proefschrift! Een aantal mensen wil ik graag in het bijzonder 
bedanken. 
 
Allereerst wil ik graag mijn promotor prof. Oudkerk bedanken. U heeft mij de mogelijkheid 
gegeven mijn promotieonderzoek op het gebied van de mammadiagnostiek te doen. Het 
opstarten van dit onderzoek verliep niet altijd even gemakkelijk, maar u heeft mij altijd 
gesteund en vertrouwen gegeven. Daar ben ik u dan ook erg dankbaar voor. Daarnaast 
hebben de besprekingen met u mij erg geïnspireerd. Ik hoop dan ook nog heel veel jaren 
met u samen te werken op het gebied van mammaonderzoek. 
 
De leescommissie, prof. dr. W.P.Th.M. Mali, prof. dr. E.G.E. De Vries en Prof. dr. V. 
Subramaniam dank ik voor hun kritische beoordeling en goedkeuring van dit proefschrift. 
 
Mijn co-promotoren Ruud Pijnappel en Paul Sijens wil ik graag bedanken voor hun 
waardevolle informatie en nuttige uitleg tijdens onze besprekingen.  
Beste Ruud, wie had ooit gedacht dat ik zou promoveren op mammaonderzoek en wie had 
ooit gedacht dat jij dan mijn copromotor zou zijn. Dit konden wij allebei niet bedenken 13 
jaar geleden toen ik voor het eerst met jou kennis maakte in het Martini Ziekenhuis. Jij was 
toen al radioloog en ik liep mijn stage als radiodiagnostisch laborant. Ik denk dat jij toen 
mij het allerbeste advies heb gegeven: “Waarom ga je niet geneeskunde studeren?” Ja, en 
nu vele jaren later wil ik mammaradioloog worden en kan ik niet anders zeggen dan dat  ik 
de juiste keuze heb gemaakt. Ik vind het een verrijking om met jou samen te werken. Ik heb 
veel geleerd van jouw ruime kennis, maar ook jouw goede begeleiding en kritische blik op 
mijn manuscripten heeft dit proefschrift tot een goed einde gebracht. Ik waardeer jou als 





Beste Paul, het eerste wat mij opviel was hoe snel jij een goed manuscript in elkaar kon 
zetten. Van jou kreeg ik dan ook altijd een snelle reactie en goed commentaar op mijn 
manuscripten. Ik heb daar heel veel van geleerd. Daarnaast kon ik elk moment van dag bij 
je aankloppen. Maar wat heb ik ook erg genoten van jouw humor. Ik hoop dat wij samen op 
het gebied van de spectroscopie nog heel veel bereiken.  
 
Ik wil de rest van de mensen die in mijn mammaprojectgroepje zaten ook persoonlijk 
bedanken voor hun bijdrage. Beste Martine, jij zou mij helpen met de statistiek, maar jij 
hebt veel meer gedaan dan dat. Jij kwam met het idee om voor mij een mammaprojectgroep 
op te starten, waar mensen uit verschillende disciplines zouden deelnemen. Wat was dat een 
goed idee van jou! Ik ben ervan overtuigd dat ik mijn onderzoek nooit zo goed had kunnen 
afronden als ik niet zo’n projectgroepje had. Daarnaast was je ook zo kritisch over mijn 
geschreven stukken. “Monique, ik wil de rode draad door het manuscript zien” zei je altijd. 
Alleen met die opmerking wist ik wat mij te doen stond. Martine, bedankt voor alles! 
Beste Peter Kappert, als systeemspecialist MRI zijn jouw meningen voor mij erg belangrijk 
geweest. Jij wist het onderzoek spectroscopie op de werkvloer in goede banen te leiden. 
Maar wij hebben samen meer gedaan met maar één doel voor ogen: alleen het allerbeste 
voor de mammadiagnostiek. Wij zijn dan ook nog lang niet klaar en ik kijk dus uit naar 
onze verdere samenwerking. 
Beste Liesbeth, als mammachirurg en als persoon ben ik erg blij dat jij wilde deelnemen in 
mijn mammaprojectgroep. Jouw kijk op mammaonderzoek uit het oogpunt van de chirurg 
is erg kostbaar geweest. We hebben samen veelzijdige gesprekken gehad in en buiten het 
ziekenhuis. Ik heb daar als persoon erg veel aan gehad. Na dit proefschrift zullen wij 
blijven samenwerken op het gebied van mammaonderzoek en ik kan dan ook niet wachten 
wat daar allemaal uit zal komen rollen. 
 
Beste Peter van Ooijen, wij hebben samen een mooi artikel gepubliceerd, maar tussendoor 
zijn wij ook bezig geweest met andere onderzoeken. Ik wil je graag bedanken voor jouw 
goede begeleiding en prettige samenwerking, maar vooral vanwege het feit dat de deur 






Irene en Annemarie wil ik heel erg bedanken voor het altijd per week een gaatje vrij te 
plannen voor een spectroscopie onderzoek. En daarnaast waren jullie erg flexibel met het 
inplannen en keken jullie ook of er een patiënt geschikt was voor mijn onderzoek. Bedankt 
voor jullie inzet!! 
Ik wil de MRI laboranten bedanken voor het scannen. Het was bij jullie ook geen probleem 
als het tijdens het avondprogramma moest gebeuren. Heel erg bedankt!! 
Theo en Sibylle, ik wil jullie graag bedanken voor jullie laagdrempeligheid voor overleg. Ik 
kon altijd bij jullie aankloppen als er iets gedaan moest worden voor een patiënt. Daarnaast 
heb ik jullie interesse en steun in mijn onderzoek erg gewaardeerd. 
Kees en Arieke, de nurse practioners van de chirurgie, wil ik graag bedanken voor hun 
toegankelijkheid. Ik kon altijd bij jullie ééndagsdiagnostiek besprekingen aanwezig zijn, 
waardoor ik veel patiënten kon includeren in mijn studie. Ook heb ik jullie meedenken erg 
op prijs gesteld. 
 
Gonda en Stella, mijn paranimfen, mijn collega’s en mijn vriendinnen, graag wil ik jullie 
als eerste bedanken dat jullie er altijd voor mij zijn en voor het onvoorwaardelijke 
vertrouwen in mij. Lieve Gonda, bedankt voor de hele mooie voorkant van mijn boekje, 
maar ook bedankt voor alle gezellige en mooie gesprekken. Wij zijn dan wel op sommige 
vlakken precies het tegenovergestelde (op tijd - laatste moment, opruimerig - niet 
opruimerig), maar op de belangrijkste dingen in ons leven voelen wij elkaar vlekkeloos aan. 
Lieve Stella, ik weet nog dat ik voor het eerst met je kennismaakte. Ik wist op dat moment 
gelijk dat het goed zat, het voelde als thuiskomen. Tijdens mijn onderzoeksproject heb je 
veel voor mij gedaan: jouw steun, jouw luisterend oor en jouw kijk op dingen hebben niet 
alleen veel bijgedragen aan dit proefschrift, maar ook voor mij als persoon. 
 
Mijn collega’s en medeonderzoekers, Hildebrand, Daniël, Wouter, Alain, Jolanda, Paul, 
Petra, Anne, Wisnu, Ying, Yingru, Dongming, en alle anderen wil ik graag bedanken voor 
de fijne sfeer op de G2 en de gezellige etentjes. Lieve Hildebrand, bedankt voor alle 







Mijn vrienden, Mirjana, Martin, Peter, Juliette, Sophie, Bas, Esther, Olivier, Jasper, Joyce, 
Gideon, Inge, Hans en Jonina: jullie hebben het voor mij makkelijker gemaakt om dit 
proefschrift af te ronden, vanwege al die gezellige uitjes en relaxte avondjes. Lieve 
Mirjana, al zo lang een hele mooie vriendschap, bedankt voor altijd je interesse in mij, maar 
vooral bedankt voor al je steun tijdens mijn promotieonderzoek en zwangerschap. Jij wist 
altijd het juiste te zeggen op de juiste momenten. Ik kan niet wachten op al die vakanties 
die gaan komen met Martin, Isabel, Evelien, René en Josephine.  
 
Mijn familie tante Greet, Wenda, Rick, Erwin, Elmora, Sifra, Yamila, Bryan, Fairleen, 
Ellen, Nel, Frans, Wesley, Maaike, Lydia, Ciska en Nathalie wil ik bedanken voor hun 
moral support (zelfs als je in Amerika woont). Lieve tante Greet, ik hoef voor jou eigenlijk 
niks op papier te zetten, want wij begrijpen elkaar al zonder woorden. Maar toch wil ik van 
deze gelegenheid gebruik maken om je te bedanken voor al je steun en toeverlaat in mijn 
leven, vooral tijdens mijn studie geneeskunde en promotietraject. Jij bent altijd op de 
hoogte van wat erin mijn leven speelt. Jouw wijze adviezen en inzicht hebben ervoor 
gezorgd dat veel dingen op zijn plaats vielen. 
Lieve Nel en Frans, bedankt dat ik altijd een slaapplek heb gehad tijdens mijn studie 
geneeskunde, maar vooral bedankt voor de belangstelling die jullie hadden voor mijn 
opleiding en mijn promotieonderzoek en natuurlijk voor de ontspannen gesprekken tijdens 
het avondeten.  
Lieve Wenda, jij bent 3 jaar geleden gepromoveerd en weet dus precies wat ik doormaak. 
Bedankt dat jij er altijd voor mij bent op de belangrijke momenten in mijn leven. 
 
Lieve pap en mam, woorden schieten te kort om jullie te bedanken, want het is te veel om 
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onvoorwaardelijke liefdevolle steun tijdens mijn leven. Bedankt dat jullie mij de 
mogelijkheid hebben gegeven om te studeren. Maar het meest bedankt voor het grote 






Als laatste maar als allerbelangrijkste wil ik graag mijn man en dochter bedanken.  
Lieve René, ik weet hoe bescheiden je bent, maar dit proefschrift was er echt niet gekomen 
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altijd tijd voor elkaar is. Ik geniet van jouw nuchterheid en humor waardoor alles in 
perspectief blijft. Ik hou ontzettend veel van jou en ik wens mijzelf dan ook nog heel veel 
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Behorend bij het proefschrift 
 
New diagnostic developments to prevent unnecessary invasive procedures 




1. Breast MRI can rule out malignancy with high confidence due to the very high 
negative predictive value. (dit proefschrift) 
 
2. Breast MRI should be used in any diagnostic strategy for the work-up of non-calcified 
BI-RADS 3 lesions to avoid unnecessary invasive procedures. (dit proefschrift) 
 
3. The clinical implication for CAD systems in assessing breast MRI is to provide easier 
and faster ways of interpreting the patterns of contrast enhancement. (dit proefschrift) 
 
4. The diagnostic performance of the experienced radiologist in evaluating breast lesions 
with breast MRI is not influenced by the use of CAD. (dit proefschrift) 
 
5. Unlike multivoxel MR spectroscopy, measurement outcomes of single-voxel MR 
spectroscopy cannot be related with certainty to the region of interest of the relevant 
breast tissue. (dit proefschrift) 
 
6. In breast MR spectroscopy, choline concentrations as a measurement of cell membrane 
metabolism have to be quantified to discriminate benign from malignant lesions.  
(dit proefschrift) 
 
7. Quantitative multivoxel MR spectroscopy can be applied to exclude benign breast 
lesions ≥ 1 cm3 from further invasive diagnostic work-up. (dit proefschrift) 
 
8. The impact of sensitivity of diagnostic tests is generally underestimated as a tool to 
exclude patients from further diagnostic work-up. 
 
9. De kosteneffectiviteit van een goed inlevingsvermogen in de patiënt is nauwelijks te 
overschatten.  
 
10. De integrale samenwerking tussen de afdelingen radiologie en chirurgie moet eigenlijk 
vanzelfsprekend zijn.  
 
11. We can suffer our entire life over a thought that may not be true. (Byron Katie) 
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